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CHAPTER 1 - INTRODUCTION
Trophoblast cells are a major embryonic component of the placenta that mediate its major
functions (Chaddha et al., 2004). As placentation proceeds the trophoblast cells differentiate and
change to accommodate the growing placenta and fetus that it supports. The goal of this project
was to better understand mechanisms that regulate trophoblast survival in both normal and
pathological human pregnancies. This chapter reviews the existing literature on growth factors
and molecular mechanisms governing blastocyst implantation and placentation.
The first 10 weeks of pregnancy are a period when O2 is low within the conceptus
(Burton and Jauniaux, 2004; Burton et al., 1999). Intrauterine measurements report low O2
concentrations in placental tissues (~2%) compared to the surrounding decidua (~8%) and other
adult tissues (Jauniaux et al., 2001; Rodesch et al., 1992).

This environment favors the

proliferation of the trophoblast cells, while repressing invasion (Genbacev et al., 1996; Genbacev
et al., 1997). As a result, trophoblast cells accumulate and occlude the maternal blood vessels,
which maintains the relatively hypoxic state (Burton and Jauniaux, 2004). The most distal
trophoblast cells contact maternal blood, exposing them to higher O2 concentrations, which
promotes the invasive extravillous trophoblast (EVT) phenotype.

As gestation progresses

beyond 10 weeks, the spiral arteries are remodeled by EVT cells to an extent that reperfuses and
fully oxygenates the placenta by dislodging the occluding trophoblast cells and removing the
arterial smooth muscle (Norwitz et al., 2001). The placenta is programmed to survive this rapid
increase in O2 tension after Week 10 to meet the demands of a growing fetus. Prolonged
hypoxia beyond Week 10 is associated with perinatal disease arising from aberrant placental
development (Soleymanlou et al., 2005). If reoxygenation does not take place in timely manner,
or if the trophoblast cells are deficient in their ability to adjust to O2 fluctuation (Hung and
Burton, 2006), uteroplacental insufficiency could result.
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Uteroplacental insufficiency, the sub-optimal perfusion of the developing placenta due to
reduced uterine artery blood flow, contributes to several perinatal disorders, including early
pregnancy loss (EPL), fetal growth restriction (FGR), and preeclampsia (PE) (Hossain and
Paidas, 2007; Papageorghiou et al., 2004). The incidence of EPL approaches 15% (Larsen et al.,
2013). FGR occurs in 4-8% of all pregnancies in developed countries, depending on the infant
size percentile used for inclusion (Kramer, 1987). PE has a frequency of about 5-7%, while the
most severe forms occur at 0.5-1%. PE is clinically defined by the presence of maternal
hypertension and proteinuria occurring after 20 weeks of pregnancy in a previously
normotensive, non-proteinuric patient (Davey and MacGillivray, 1988).

Maternal death or

serious long-term morbidity can occur, while abruption, preterm delivery and FGR contribute to
perinatal fetal death and infant morbidity, with the associated costs of extensive neonatal
hospitalization, and lifelong disabilities (Roberts et al., 1998). Until recently, PE could be
alleviated only by removal of the placenta (Roberts et al., 1998), requiring delivery of the fetus
and accounting for 15% of premature deliveries and the associated infant morbidity and
mortality (Meis et al., 1998). More recently, interventional efforts such as the introduction of a
low dose aspirin (Bujold et al., 2014) or Pravastatin (Ramma and Ahmed, 2014) regimen prior to
16 weeks of gestation have shown promise in reducing the rate of PE in high-risk patients,
providing a course of action when diagnosed early.
Histological features of placentas delivered by women with EPL, PE and FGR suggest a
prior disruption of EVT function in the first trimester (Burton and Jauniaux, 2004), characterized
by reduced trophoblast invasion, insufficient remodeling of the spiral arteries, and EVT cell
death (Brosens et al., 1972; DiFederico et al., 1999; Ishihara et al., 2002; Khong et al., 1986).
Evidence strongly indicates that remodeling of the uterine arteries becomes deficient before PE
and FGR are diagnosed, yet direct confirmation of early EVT dysfunction is lacking, and the
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underlying etiologic cellular and molecular mechanisms are unknown due largely to our inability
to interrogate the gestational period of interest. A large number of predictors for FGR and PE
have been proposed with variable results (Bastek and Elovitz, 2013; Hossain and Paidas, 2007;
Papageorghiou et al., 2004; Staff et al., 2013). First trimester screening of multiple predictors
remains uninformative even when combined in a multivariable model (Myatt et al., 2012). At
best, screening at any GA is limited to predicting early severe PE. Therefore, no reliable
biomarkers are available to alert clinicians in the first trimester to identify pregnancies that will
eventually develop FGR or PE, impeding progress toward targeted management of at-risk
pregnancies to lessen the impact on women and their fetuses.
While access to fetal cells for prenatal diagnosis is technically complex and in some cases
high risk (Wapner, 2005), a relatively simple solution to this challenge has been advanced over
the past forty years (Adinolfi and Sherlock, 2001; Bischoff and Simpson, 2006; Imudia et al.,
2010; Shettles, 1971). Trophoblast cells shed into the lower uterine pole accumulate within the
cervix. Scientists and clinicians have tried to harness the information of trophoblast cells in the
endocervical canal, but were largely unsuccessful due to the inability to purify these cells.
Trophoblast retrieval and isolation from the cervix (TRIC) (Bolnick et al., 2014) efficiently
separates maternal cells from fetal cells that resemble EVT cells in endocervical specimens.
TRIC provides ample amounts of fetal DNA, RNA and protein for molecular analyses. Fetal
cells obtained by TRIC as early as 5 weeks of gestation can be used in genomic, epigenomic,
transcriptomic, metabolomic or other global discovery paradigms. Therefore, TRIC provides the
opportunity to investigate the molecular profiles of trophoblast cells in the first trimester from
pregnancies with known outcomes.

Indeed, a pilot study using TRIC has demonstrated

significant differences between protein biomarkers produced by the fetal cells before 10 weeks
of gestation in normal control pregnancies and those that ended with an EPL (Fritz et al., 2015a).
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The survival and extravillous differentiation of trophoblast cells is crucial for normal
pregnancy, and deficiencies are linked to diseases of placental insufficiency (e.g. EPL, FGR,
PE). Heparin-binding EGF-like growth factor (HBEGF) acts as a trophoblast survival factor,
protecting the first trimester trophoblast cells from apoptosis during exposure to low O2 levels
(Armant et al., 2006), and promoting their invasion of maternal tissues (Leach et al., 2004).
Conversely the hypertensive disease, PE, in which trophoblast invasion of the uterine arteries is
reduced (Khong et al., 1986) and apoptosis elevated (Allaire et al., 2000), is associated with a
dramatic reduction in HBEGF expression (Leach et al., 2002a). This suggests that the survival
of trophoblast cells at the beginning of pregnancy might be disrupted by reduced HBEGF in
women who later develop PE. However, it is not known whether the decreased expression of
HBEGF in preeclamptic placentas occurs prior to delivery, which would indicate whether
dysregulation is a cause or result of disease. Recently, these findings were confirmed and
extended to other components of the epidermal growth factor (EGF) family (Armant et al.,
2015), of which HBEGF is a member.
Epidermal growth factor (EGF) signaling system
The EGF family of growth factors and their receptors regulate a variety of biological
processes that include proliferation, differentiation and survival. Growth factors in the EGF
superfamily include EGF, HBEGF, transforming growth factor-alpha (TGFA), amphiregulin
(AREG), betacellulin (BTC), epiregulin (EREG), epigen and the neuregulins (NRG) (Holbro and
Hynes, 2004; Riese and Stern, 1998). Recent studies have examined the roles of each EGF
family member in implantation and placentation.
The EGF-like growth factors activate receptor tyrosine kinases in the plasma membrane
that include epidermal growth factor receptor (EGFR/ERBB1) and related ERBB family proteins
(ERBB2, ERBB3, ERBB4). Growth factor binding initiates an intrinsic protein-tyrosine kinase
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activity, autophosphorylation of the cytoplasmic domain and receptor dimerization to generate a
downstream signaling cascade (Holbro and Hynes, 2004). The EGF-like growth factors are
synthesized as membrane bound proteins that signal to their receptors on adjacent cells, through
juxtacrine signaling, or they are secreted through proteolytic cleavage of their extracellular
domain, carried out by metalloproteinases, for autocrine or paracrine signaling (Riese and Stern,
1998).
Mouse implantation
The importance of the EGF signaling system for blastocyst implantation is suggested by
the EGFR knockout (Miettinen et al., 1995; Sibilia and Wagner, 1995; Threadgill et al., 1995),
which, depending on the genetic background of host mice, has a perinatal-lethal phenotype.
However, the picture is less clear from studies of embryos with deletion of EGF family growth
factors where several knockouts produce mice that are viable and fertile, while others have roles
in early post-implantation embryonic development that make interpretation difficult. It remains
to be determined whether the EGF signaling system has a specific role in the process of
implantation, or if it is more involved in embryonic survival and differentiation. Alternative
approaches provide evidence to support the hypothesis that this complex signaling system
directly influences the success of blastocyst implantation.
Experiments in mice establish that HBEGF is present in the uterus shortly before embryo
implantation, providing the earliest known signaling between the blastocyst and maternal cells
(Lim and Dey, 2009). In situ hybridization demonstrates that HBEGF is expressed in the
luminal epithelium specifically at sites surrounding blastocysts 6-7 hours prior to the attachment
reaction (Das et al., 1994). HBEGF is also expressed by blastocysts prior to implantation (Liu
and Armant, 2004), suggesting its role in a two-way dialogue. Experimentally induced delayed
implantation in ovariectomized mice reveals no HBEGF expression at implantation sites;
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however, HBEGF becomes upregulated in both the uterus (Das et al., 1994) and blastocyst
(Hamatani et al., 2004) with administration of estrogen to activate the blastocyst to implant. Its
receptors ERBB1 and ERBB4 are concomitantly regulated by estrogen along with HBEGF in the
blastocyst (Paria et al., 1993; Paria et al., 1999). HBEGF signaling between the trophoblast and
uterine epithelial cells is most likely initiated by embryonic HBEGF shedding, as depicted in
Figure 1A.Crosstalk with other signaling pathways mobilizes HBEGF from intracellular stores in
the trophectoderm and demonstrates the complexity of the maternal-embryo dialogue.
Lysophosphatidic acid (LPA) produced in the maternal reproductive tract accelerates blastocoel
formation at the morula stage and trophoblast differentiation at the early blastocyst stage through
downstream intracellular Ca2+ signaling (Liu and Armant, 2004; Stachecki and Armant, 1996).
LPA activates cognate G protein-coupled receptors that signal through phospholipase C to
generate inositol-1,4,5-trisphosphate and diacylglycerol that, in turn, mobilize cytoplasmic free
Ca2+ and activate protein kinase C (PKC), respectively (Contos et al., 2000). Signaling by both
cytoplasmic Ca2+ and PKC is known to stimulate HBEGF shedding (Dethlefsen et al., 1998;
Dong and Wiley, 2000) and the subsequent transactivation of ERBB signaling (Umata et al.,
2001). Immunofluorescence microscopy demonstrates that HBEGF is sequestered from the
plasma membrane during blastocyst development, but accumulates transiently at the embryo
surface in response to LPA-induced intracellular Ca2+ release (Liu and Armant, 2004).
Therefore, uterine LPA secretion could activate HBEGF shedding from blastocysts in opposition
to the uterine wall, signaling its presence to the adjacent uterine epithelium (Figure 1A).
Several studies support the hypothesis that expression of HBEGF in the peri-implantation
endometrial epithelium is induced by embryo derived HBEGF signaling. HBEGF is expressed
in both mouse and hamster preimplantation blastocysts (Hamatani et al., 2004; Liu and Armant,
2004; Wang et al., 2002). Interestingly, when growth factor-soaked beads the approximate size
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Figure 1. Heparin binding EGF-like growth factor (HBEGF)- signaling and cell differentiation
during implantation in mice. Blastocyst-uterine interactions shown at the top of the diagram illustrate
the (A) apposition, (B) attachment and (C) invasion stages of implantation. The regions within the green
boxes are expanded below to summarize signaling pathways that orchestrate trophoblast and uterine
epithelial cell differentiation at each stage, as discussed in the text. Arrows depict growth factor secretion
or shedding, binding to receptors, intracellular trafficking, ion influx, and de-repression in the case of
TRO and ERBB4. Double lines indicate juxtacrine signaling and/or cell-cell adhesion. ECM,
extracellular matrix; HBEGF, heparin-binding EGF-like growth factor; ITGA, integrin alpha subunit;
ITGB, integrin beta subunit; LPA, lysophosphatidic acid; LPAR, LPA receptor; N, N-type voltage-gated
Ca2+ channel; PKC, protein kinase C; PLC, phospholipase C; TRO, trophinin; X, indicates apoptosis
induced by nuclear localization of PKCδ

of blastocysts are transferred into the uteri of pseudo pregnant mice only HBEGF and insulinlike growth factor-1 (IGF1) provoke discrete implantation-like responses (Paria et al., 2001).
Furthermore, highly localized expression of HBEGF occurs in the uterine epithelium adjacent to
apposition stage blastocysts (Das et al., 1994). These studies suggest a positive feed-forward
regulation of uterine HBEGF expression initiated by the blastocyst during the apposition stage of
implantation. While HBEGF secreted by the embryo is sufficient to induce HBEGF expression
in the luminal epithelium, other factors secreted by embryos (e.g., IGF1) could have equivalent
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activity and perhaps compensate in HBEGF deficient embryos, which are able to implant
normally when transferred to wild type pseudopregnant dams (Xie et al., 2007).
HBEGF protein appears on the surface of the uterine epithelium early on gestation day 5
in mice as the attachment reaction commences (Das et al., 1994). The primary target of HBEGF
in the luminal epithelium is the trophoblast (Figure 1B). Late on day 4, HBEGF signaling in the
blastocyst becomes robust as a result of ERBB4 trafficking to the trophoblast surface (Wang et
al., 2000). ERBBs 1-3 are already localized at the apical surface as the blastocyst forms.
However, ERBB4 is the preferred receptor for HBEGF in blastocysts (Paria et al., 1999). Thus,
ERBB1 and ERBB4 both become available on the trophoblast at approximately the time when
uterine HBEGF first appears.

These events position HBEGF and its receptors to mediate

blastocyst adhesion and trophoblast differentiation.
HBEGF-induced

ERBB

autophosphorylation

advances

trophoblast

adhesive

differentiation (Das et al., 1994; Paria et al., 1999; Wang et al., 2000). In blastocysts cultured
serum-free, HBEGF induces trafficking of integrin subunits, including ITGA5 (Figure 1B), into
the plasma membrane of trophoblast cells approximately 24 hours earlier than in control
embryos, which promotes their adhesion to fibronectin in the maternal extracellular matrix
(Wang et al., 2000). In vitro experiments suggest that after apoptosis of the opposing luminal
epithelial cells, ligation of the integrin ITGA5/ITGB1 by the exposed basement membrane
activates phospholipase Cg (Wang et al., 2007), leading to trafficking of ITGA2B into the
plasma membrane (Rout et al., 2004), which strengthens cell adhesion as trophoblast invasion
commences (Figure 1C).
Experiments have been reported suggesting that HBEGF supports the attachment reaction
during implantation in addition to its ability to advance hatching and trophoblast differentiation.
Using engineered cells that express membrane bound HBEGF to simulate receptive uterine
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epithelial cells, it has been demonstrated that cell surface HBEGF binds to day 4 mouse
blastocysts, but not to delayed blastocysts (Raab et al., 1996). HBEGF signaling activates Ca2+
influx across the plasma membrane through N-and calmodulin, consequently accelerating
trophoblast invasion (Wang et al., 2000). It appears that there are complex autocrine, paracrine
and juxtacrine pathways that integrate HBEGF signaling with input from other growth factors, as
well as through cell-cell interactions between the trophectoderm and uterine epithelium during
implantation (Figure 1).
Maternal HBEGF deficiency targeted to the uterus defers the window of implantation and
compromises pregnancy outcome, thus, implicating the importance of two-way communication
between the embryo and the uterus (Xie et al., 2007).

However, another heparin-binding

member of the EGF family, AREG, partially compensates for HBEGF loss.

Progesterone

upregulates AREG throughout the uterine luminal epithelium of the mouse early on gestation
day 4 independently of the blastocyst (Das et al., 1995), but it becomes restricted to the
implantation site by day 5. Studies conducted to clarify the mechanism of AREG signaling at
the embryonic-maternal interface suggest that the presence of fertilized embryos in the
reproductive tract elevates expression of AREG on day 4 (Lee et al., 2006). Therefore, the
presence of embryos in an HBEGF-deficient uterus could induce partially-compensating
production of AREG, which can activate only ERBB1 (Riese and Stern, 1998).
Another EGF family member, TGFA, has extensive sequence homology to EGF and
comparable affinity for ERBB1, its only receptor. Immunohistochemical, in situ hybridization,
northern blot and RT-PCR analyses clearly demonstrate TGFA expression in the uterus and
embryo (Rappolee et al., 1988; Tamada et al., 1991). Additionally, a reduction in the number of
implantation sites in rats after administration of intraluminal anti-TGFA injections supports the
involvement of TGFA in implantation (Tamada et al., 1997). Addition of TGFA to in vitro
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culture medium is favorable for preimplantation embryo development and trophoblast
differentiation (Haimovici and Anderson, 1993; Machida et al., 1995).

However, this

involvement is controversial, as TGFA knock out mice have normal implantation (Luetteke et
al., 1993; Mann et al., 1993). Similarly, AREG and EGF are not essential for implantation,
indicated by mice deficient in AREG and triple knockout mice lacking TGFA, AREG and EGF,
which are all fertile (Luetteke et al., 1999). These studies support the concept of a compensatory
response by other EGF family members, perhaps HBEGF, during implantation.
Another group of EGF-like growth factors that mediate cell-cell interactions, the NRGs,
are encoded by four distinct genes, NRG-1, NRG-2, NRG-3 and NRG-4 (Burden and Yarden,
1997; Falls, 2003). There is evidence for 15 splice variants of NRG-1 that are grouped into three
subtypes (Ben-Baruch and Yarden, 1994; Meyer et al., 1997). Of the three subtypes, Type 1 is
comprised of neu differentiation factor (NDF), heregulin and acetylcholine receptor-inducing
activity (Ben-Baruch and Yarden, 1994). Type 2 consists of the glial growth factor (GGF) and
type 3 comprises the sensory and motor neuron derived factor (SMDF) (Brown et al., 2004).
NDF and its isoforms are expressed in the preimplantation mouse uterus (Reese et al., 1998).
Mice with delayed implantation do not express NDF; however, upon administration of estrogen,
the expression of NDF returns. Alternately there is evidence that SMDF has a similar cellular
distribution to NDF and its expression becomes prominent at the time of implantation (Brown et
al., 2004). However, no significant expression of GGF is observed in the peri-implantation
uterus. In the blastocyst, both ERBB3 and ERBB4 are present on trophoblast cells, suggesting
the capacity for signaling with NRG family members (Wang et al., 2000). A parallel study
observed a similar expression pattern of the EGF family members BTC and EREG (Das et al.,
1997), suggesting that optimal expression of NDF, BTC and EREG requires an activated
blastocyst. Therefore, it remains possible that these EGF family members contribute to mouse
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implantation.
Human implantation
In contrast to its regulation in mice that have a short estrus cycle, HBEGF is regulated
independently of the presence of an embryo in the stromal and epithelial compartments during
the menstrual cycle of the human endometrium (Chobotova et al., 2002a; Leach et al., 1999; Yoo
et al., 1997).

There is evidence that HBEGF mediates maternal-blastocyst signaling and

attachment in humans as it does in rodents owing to the switch in expression of HBEGF mRNA
and protein from the subepithelial stroma during early secretory phase to glandular and luminal
epithelium in the mid-secretory phase (Leach et al., 1999).

ERBB4 is expressed by the

trophoblast cells of human peri-implantation blastocysts, suggesting that HBEGF present in the
luminal epithelium could stimulate the blastocyst through paracrine or juxtacrine signaling
(Chobotova et al., 2002b). HBEGF not only accelerates the development of human embryos to
the blastocyst stage, but also aids in hatching from the zona pellucida (Martin et al., 1998).
Evidence indicates that proliferation in human endometrial stromal cells is regulated by
both the soluble and transmembrane forms of HBEGF, along with other EGF family members,
EGF and BTC, suggesting key functions for the EGF family of growth factors in regeneration
and maturation of the human endometrium and to prepare the embryo for implantation
(Chobotova et al., 2002a). However, this induction is under the cooperative effect of TNF.
Another study shows that the endometrial stromal cells produce both the soluble and
transmembrane forms of HBEGF to regulate TNF and TGFB (Chobotova et al., 2005). This
provides a survival function that prevents apoptosis of endometrial cells exposed to apoptotic
factors, which highlights the importance of HBEGF and its receptors in the human endometrium.
HBEGF appears to participate in a broader dialogue that includes other molecules,
exemplified by trophinin-bystin signaling.

Both human trophoblast cells and the uterine
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epithelium express the transmembrane protein trophinin that mediates cell adhesion through
homophilic binding (Suzuki et al., 1999). Trophinin forms a complex with its cytoplasmic
partner bystin and ERBB4, which inhibits ERBB tyrosine phosphorylation required for invasive
trophoblast differentiation (Figure 1B). However, during the attachment reaction between the
blastocyst and luminal epithelium, homophilic trophinin binding releases bystin, thus
derepressing ERBB4, which can then become activated by HBEGF to promote trophoblast differentiation (Sugihara et al., 2007; Tamura et al., 2011). Meanwhile, in the luminal epithelium,
homophilic trophinin binding disrupts its tethering of protein kinase Cδ to the plasma membrane,
freeing the latter to enter the nucleus where it induces apoptosis (Tamura et al., 2011). Thus,
trophinin signaling removes the cellular barrier to blastocyst implantation as it licenses activation
of trophoblast adhesion competence.
Human placentation
Most components of the EGF signaling system are present throughout pregnancy.
Transcripts from placental tissues obtained in all three trimesters demonstrate expression of
HBEGF, with the highest abundance in first trimester decidua (Yoo et al., 1997). Strong staining
for HBEGF is observed in villous and EVT cells in both normal placentas and those delivered
preterm (Leach et al., 1999; Leach et al., 2002a). Other EGF family members and ERBB
receptor tyrosine kinases are expressed in placental trophoblast populations (Hofmann et al.,
1992; Tanimura et al., 2004), indicating that the EGF signaling system is highly active during
placental development.
There is evidence to support the hypothesis that HBEGF, and possibly other EGF family
members, promote trophoblast invasion (Jessmon et al., 2009).

The capacity for invasion

weakens as gestation progresses (Damsky et al., 1994; Librach et al., 1991), indicating the
importance of the EGF signaling system in first trimester trophoblast cells (Bass et al., 1994).
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EGF, TGFA and HBEGF can stimulate first trimester trophoblast cells to become invasive and
differentiate to the extravillous phenotype (Bass et al., 1994; Leach et al., 2004). However, the
effectiveness of EGF diminishes with trophoblast cells obtained from the second or third
trimester (Bass et al., 1994), suggesting that their loss of invasion competence is intrinsic rather
than a product of their environment. Invading EVT cells are necessary for adequate remodeling
of the uterine spiral arteries that perfuse the developing placenta (Norwitz et al., 2001).
The widespread expression of HBEGF in placental trophoblast cells and surrounding
decidua (Leach et al., 1999) could facilitate invasion and contribute to remodeling of the spiral
arteries.

It has been demonstrated that when the HTR-8/SVneo human first trimester

cytotrophoblast cell line is cultured at 2% O2, HBEGF, but not other EGF family members, is
upregulated and secreted (Armant et al., 2006). However, trophoblast cells in villous explants
from term placentas do not elevate HBEGF in response to low oxygen and their survival is
compromised by hypoxia (Imudia et al., 2008). Addition of HBEGF to term villous explants
cultured at 2% O2 inhibits apoptosis, demonstrating its capacity as a survival factor.
Because the placenta is programmed to survive at a low O2 tension during the first
trimester, trophoblast invasion progresses slowly at the vascular interface, delaying the full onset
of placental perfusion for ten weeks (Norwitz et al., 2001). However, if reoxygenation does not
occur on time, placental insufficiency ensues, and, depending on severity, can result in EPL,
FGR or PE (Burton and Jauniaux, 2004). These disorders are associated with poor trophoblast
invasion and increased apoptosis (Brosens et al., 1972; DiFederico et al., 1999), two functions
that are strongly regulated by HBEGF signaling (Jessmon et al., 2009). Placental tissues from
preeclamptic pregnancies have reduced expression of HBEGF compared to gestational agematched normotensive placentas, as well as reduced HBEGF mRNA expression (Leach et al.,
2002a). There are also deficiencies in EGF and TGFA, as well as increased production of a
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secreted form of EGFR that binds EGF-like growth factors to antagonize signaling through
ERBB receptors (Armant et al., 2015). These findings suggest the hypothesis that reduced
HBEGF expression could contribute to the shallow trophoblast invasion and poor survival
observed in preeclampsia. It remains to be established whether the reduced expression of
HBEGF precedes the onset of preeclampsia, or if it is merely associated with late placental
demise. There is also clinical evidence of HBEGF disruption associated with infertility in
women (Aghajanova et al., 2008). The decreased HBEGF expression in infertile couples was
not confirmed in a larger clinical study, but it was noted that a significant increase between the
early and mid-secretory phases was absent in the infertile patients (Leach et al., 2012).
Significant advancements have been made in unraveling the molecular mechanisms
governing growth factors involved in implantation and trophoblast invasion. The mouse has
provided a powerful experimental model; however, its correlation with human implantation and
trophoblast development is not entirely consistent. In the mouse trophoblast invasion is shallow
(Redline and Lu, 1989), the arteries and blood vessels of the decidua are lined by endothelium
rather than trophoblast (Adamson et al., 2002; Redline and Lu, 1989). In humans, trophoblasts
are responsible for vascular remodeling (Pijnenborg et al., 2006), while uterine natural killer
cells are more important in the mouse (Monk et al., 2005). The differences in trophoblast
invasion and vascular remodeling in humans compared to the mouse make it a suboptimal model
for studying placental insufficiencies.
A better understanding of the molecular mechanisms governing the expression of growth
factors in implantation and placentation could better define the window of implantation.
Furthermore, this additional information could provide a foundation for development of new
treatments for clinical pathologies such as recurrent pregnancy loss and placental insufficiencies
that reduce fetal growth or contribute to PE. In considering the signaling pathways disrupted by
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obstetric disease it might be possible to devise new strategies for pharmaceutical intervention to
improve maternal-fetal care.

Therefore, continued investigation of growth factors and the

molecular mechanisms that ensure successful implantation and placentation has significant
clinical relevance. The significance of HBEGF signaling during human pregnancy will not be
fully appreciated without more sophisticated experimental approaches that take into account its
interactions with other signaling pathways. Other pathways that regulate HBEGF and alter its
expression in obstetric disease might lie closer to the root cause of placental insufficiencies, and
would provide superior targets for intervention strategies. Therefore, global approaches to this
subject are needed in addition to a targeted analysis of the role for HBEGF in placental
development and pathology.
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CHAPTER 2 - TROPHOBLAST SURVIVAL SIGNALING DURING HUMAN
PLACENTATION REQUIRES HIF-INDUCED TRANSCRIPTION OF HSP70
Abstract
Survival of trophoblast cells in the low oxygen environment of human placentation
requires metalloproteinase-mediated shedding of HBEGF and downstream signaling. A matrix
metalloproteinase (MMP) antibody array and quantitative RT-PCR revealed upregulation of
MMP2 post-transcriptionally in human first trimester HTR-8/SVneo trophoblast cells and
placental explants exposed to 2% O2. Specific MMP inhibitors established the requirement for
MMP2 in HBEGF shedding and upregulation. Hypoxia inducible factors, HIF1A and EPAS1
(HIF2A), accumulated at 2% O2, and HIF target genes were identified by next-generation
sequencing of RNA from trophoblast cells cultured at 2% O2 for 0, 1, 2 and 4 hrs. Of nine genes
containing HIF-response elements upregulated at 1 hour, only HSPA6 (HSP70B’) remained
elevated after 4 hours. The HSP70 chaperone inhibitor VER155008 blocked upregulation of
both MMP2 and HBEGF at 2% O2, and increased apoptosis.

However, both HBEGF

upregulation and apoptosis were rescued by exogenous MMP2.

We propose that MMP2-

mediated shedding of HBEGF, initiated by HSP70, contributes to trophoblast survival at the low
O2 levels encountered during the first trimester, and is essential for successful pregnancy
outcomes.
Introduction
In humans, the placenta is not fully perfused with oxygenated maternal blood until after
the tenth week of pregnancy, rendering the implantation site a low O2 environment (Burton,
2009; Burton et al., 1999; Jauniaux et al., 1991). Atypical of most cells, human trophoblast cells
not only survive at low O2, but also proliferate more rapidly (Genbacev et al., 1996; Genbacev et
al., 1997; Kilburn et al., 2000). The epidermal growth factor (EGF) family member, heparin-

17
binding EGF-like growth factor (HBEGF) is highly expressed in the uteroplacental compartment
during implantation and early placentation (Jessmon et al., 2009). We previously reported that
HBEGF prevents death of human trophoblast cells exposed to low O2 concentrations (Armant et
al., 2006). Although HBEGF is upregulated ~100-fold in trophoblast cells after exposure to 2%
O2, HBEGF mRNA remains unchanged and is abundant (2500 copies/cell) at both O2
concentrations (Armant et al., 2006). Survival of trophoblast cells at low (2%) O2 requires
metalloproteinase-mediated shedding of membrane-bound proHBEGF and HBEGF downstream
signaling (Armant et al., 2006). HBEGF is synthesized as transmembrane proHBEGF, and
secreted through shedding from the plasma membrane by proteolytic cleavage, allowing it to
activate ERBB receptor tyrosine kinases, including its cognate receptors, EGF receptor/ERBB1
and ERBB4 (Holbro and Hynes, 2004).

As O2 increases with the full perfusion of the

intravillous space after 10 weeks of gestation (Burton, 2009; Burton et al., 1999; Jauniaux et al.,
1991), HBEGF positively regulates trophoblast motility and invasion (Jessmon et al., 2010;
Leach et al., 2004). The hypertensive pregnancy disorder, preeclampsia, in which trophoblast
invasion is reduced and apoptosis elevated, is characterized by a reduction in HBEGF and other
components of the EGF signaling system (Armant et al., 2015; Jessmon et al., 2009; Leach et al.,
2002a).

It can, therefore, be hypothesized that HBEGF production could be a factor in

trophoblast dysfunction associated with placental insufficiency disorders.
In human trophoblast cells, HBEGF activates p38 (MAPK14), ERK (MAPK1), and JNK
(MAPK8) (Jessmon et al., 2010). During hypoxia, HBEGF upregulates its biosynthesis through
an autocrine feedback mechanism, and prevents apoptosis through a parallel signaling pathway
(Armant et al., 2006; Jessmon et al., 2010). Activation of ERBB receptor tyrosine kinase by
HBEGF prevents apoptosis through a mechanism mediated by p38 MAPK, while autocrine
upregulation of HBEGF appears to be mediated by any one of the MAPKs, p38, ERK, or JNK,
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based on experiments using specific inhibitors (Jessmon et al., 2010). However, it is unclear
whether the MAPKs specifically function downstream of HBEGF in its autocrine upregulation,
or also operate further upstream in the cascade initiated by hypoxia to regulate proHBEGF
shedding.
It is well established that metalloproteinases contribute to invasion and tissue remodeling
(Loffek et al., 2011; Stamenkovic, 2003). Successful implantation and trophoblast invasion are
closely linked to the expression of matrix metalloproteinases (MMPs) that degrade basement
membranes (Librach et al., 1991). The gelatinases (gelatinase A/MMP2; 72-kDa, and gelatinase
B/MMP9; 92-kDa), which target major components of basement membranes (e.g., collagen IV),
are expressed by trophoblast cells, and therefore, regarded as key to the invasion process (Isaka
et al., 2003). MMP2 and MMP9 are differentially expressed in first trimester trophoblast cells,
with MMP2 more prominently secreted until 9 weeks (Staun-Ram et al., 2004; Xu et al., 2000).
MMP2 is constitutively expressed in trophoblast cells throughout pregnancy, but its activity is
diminished in the full-term placenta. MMP9 is mainly expressed by trophoblast cells during the
period after Week 9, and also decreases at term. Thus, MMP2 and MMP9 are expressed and
functioning throughout the periods of low and then elevated O2 in the reproductive tract,
characterized by high trophoblast proliferation and then elevated invasion, respectively
(Jovanovic et al., 2010; Librach et al., 1991). While their role in tissue remodeling is well
known (Loffek et al., 2011; Stamenkovic, 2003), emerging evidence reveals that MMPs also
participate in shedding of membrane-anchored signaling molecules, which contributes to
chemokine and growth factor activation (Burton, 2009; Chow and Fernandez-Patron, 2007;
Powell et al., 1999).
Shedding is mediated by membrane-type MMPs and MMPs bound to membrane
receptors, including MMP2 and MMP9 (Sternlicht and Werb, 2001). Cheng et al reported that
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bradykinin-induced proliferation of rabbit corneal cells is blocked by an inhibitor of both MMP2
and MMP9, as well as an inhibitor of HBEGF, suggesting that an MMP could contribute to the
cleavage of proHBEGF (Cheng et al., 2012). MMP2 participates in a proteolytic cascade in
αT3-1 cells that directs both proHBEGF shedding and EGFR transactivation (Roelle et al.,
2003). In addition, its rapid release in CMTC9 cells after E2 stimulation is correlated with
cleavage of proHBEGF (Torres et al., 2009). We previously found that treatment with a general
metalloproteinase inhibitor blocks HBEGF accumulation in human trophoblast cells at low O2,
causing apoptosis that is rescued with recombinant HBEGF, but not other EGF-like ligands
(Armant et al., 2006). Autocrine HBEGF activity in trophoblast cells requires, in addition to

metalloproteinase-mediated shedding of HBEGF, binding to either EGFR or ERBB4. Blocking
HBEGF signaling prevents its upregulation at 2% O2, suggesting that low levels of resident
proHBEGF are cleaved through activation of metalloproteinases to initiate its autocrine
accumulation downstream of ERBB receptors in a positive feedback loop.
To understand the molecular mechanism of trophoblast survival at low O2, the HTR8/SVneo human trophoblast cell line (Graham et al., 1993) was used. The HTR-8/SVneo cell
line is an immortalized cell line (Graham et al., 1998) that was established from human firsttrimester cytotrophoblast cells (Graham et al., 1993). HTR-8/SVneo cells express cytokeratin
(KRT7), a marker for trophoblast and other epithelial cells, as well as the beta subunit of human
chorionic gonadotropin (β-hCG), which is trophoblast-specific (Kilburn et al., 2000). This cell
line possesses the ability to invade Matrigel basement membrane without being tumorigenic, and
expresses the trophoblast-specific major histocompatibility protein, HLA-G, when induced by
Matrigel differentiate (Kilburn et al., 2000). In response to Matrigel, HTR-8/SVneo cells switch
integrin expression (Damsky) in association with invasive differentiation, while in response to
hypoxia, proliferation increases and extravillous differentiation is inhibited (Kilburn et al., 2000).
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To examine the hypothesis that MMPs contribute to the shedding and upregulation of HBEGF at
low O2 concentrations required for trophoblast survival in the first trimester, we used HTR8/SVneo human trophoblast cells, with confirmatory experiments using first trimester villous
explants (Castellucci et al., 1990; Genbacev et al., 1992).
Materials and Methods
Cell Culture and Treatments
The first trimester human TB cell line, HTR-8/SVneo (Graham et al., 1993), was grown
in either 96-well culture plates (approx. 500,000 cells) or T25 tissue culture flasks (approx. 85%
confluency) during experiments in sterile DMEM/F-12 with 1 mg/ml BSA at either 20% O2 or
2% O2. Cells were treated by adding to the culture medium 1-10 μg/ml α-amanitin (SigmaAldrich), 250 μM CoCl2 (Sigma-Aldrich), inhibitors (EDM Chemicals, Inc., Gibbstown, NJ)
specific for MMP2 and MMP9 (BiPS; (2R)-[(4-Biphenylylsulfonyl)amino]-N-hydroxy-3phenylpropionamide; 100 nM; MMP-2 (IC50 = 310 nM) and MMP-9 (IC50 = 240 nM)) (Tamura
et

al.,

1998),

MMP2

only

[(2-((isopropoxy)-(1,1′-biphenyl-4-ylsulfonyl)-amino))-N-

hydroxyacetamide; 250 nM; IC50 = 12 nM (at high concentration inhibits MMP-9 and MMP-3
(IC50 = 0.2 and 4.5 µM, respectively)] (Rossello et al., 2004), or MMP9 only [MMP9 Inhibitor I;
100 nM MMP-9; IC₅₀ = 5 nM (at high concentration inhibits MMP-1 (IC₅₀ = 1.05 µM) & MMP13 (IC₅₀ = 113 nM)] (White et al., 2006), specific inhibitors for ERK, JNK, and p38 (Jessmon et
al., 2010), HSP70 inhibitor (VER-155008, Santa-Cruz Biotech; 0.05-100 μM), and 10 nM
recombinant MMP2 (R&D Systems; rMMP2;).

For protein analysis, attached cells were

extracted using cell lysis buffer (Cell Signaling), and total cellular protein concentrations were
determined using Pierce BCA protein assay kit (ThermoFisher Scientific). The HTR-8/SVneo
cell line was maintained in DMEM/F12 with 10% donor calf serum at 20% O2 between passages
30-50, and routinely checked for production of β-hCG, KRT7, and when cultured on Matrigel,
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HLA-G (Graham et al., 1993; Kilburn et al., 2000). Serum was replaced with BSA 24 h before
all experiments.
Villous Explant Culture
Placental tissues were obtained with Wayne State University Institutional Review Board
approval and patient informed consent from first trimester terminations at a Michigan family
planning facility. Within a 2-hr period, fresh tissue was collected, placed on ice in PBS,
transported to the laboratory, and villous explant cultures were prepared (Bolnick et al., 2015).
The chorionic villi were dissected into pieces of approximately 5 mg wet weight and transferred
individually into DMEM/F12 culture medium supplemented with 10% donor calf serum, 100
I.U. penicillin and 100 μg/ml streptomycin in a 24-well culture plate (Costar, Corning, NY). The
explants were culture overnight at either 8% or 2% O2 then treated as described for the cell line.
Antibody Arrays
Cell lysates (1 mL) were incubated overnight with antibody array membranes, using a
human MMP antibody array kit (Abcam, Cat # ab134004). The membranes were washed and
incubated with a secondary biotin-conjugated antibody, followed by incubation with horseradish
peroxidase conjugated streptavidin, according to the manufacturer’s direction. The arrays were
developed, using enhanced chemiluminescence, and imaged on the ChemiDoc Imaging System
(BioRad). Labeling of each protein in the array was quantified using ImageJ software (NIH
http://rsbweb.nih.gov/ij/). The mean of six negative controls was subtracted for background
correction, and the mean of six positive controls was used to normalize the data and calculate the
relative expression levels.
Western Blotting
Western blots were performed as previously described (Kilburn et al., 2000). Briefly,
cellular lysates were diluted in SDS sample buffer containing 5% β-mercaptoethanol, run on
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precast 4%–20% Tris-HCl gradient gels (BioRad), and blotted with antibodies against MMP2,
MMP9, HIF1A (R&D Systems), HIF2A/EPAS1 (Novus Biologicals) and HSPA6 (Abcam)
diluted 1:1000 in TTBS and 5% milk. Densitometry was used to quantify grey levels of protein
bands of interest, using image analysis software (SimplePCI, Hamamatsu). Background grey
levels, determined in a blank lane, were subtracted to obtain the specific grey level for each
band. Band intensities were below saturation, although linearity was not determined.
ELISA
Cells were cultured and treated in six-well plates. ELISA was conducted using HBEGF,
MMP2, HIF1A and HIF2A DuoSet ELISA Development kits (R&D Systems). The optical
density of the final reaction product was determined at 450 nm using a programmable multiplate
spectrophotometer (Power Wave Workstation; Bio-Tek Instruments) with automatic wavelength
correction. Data are presented as nanograms (ng) of HBEGF or MMP2 per microgram (μg) of
total protein, determined using standard curves generated with the respective recombinant
proteins (R&D Systems).
Immunohistochemistry
Immunohistochemistry was performed using a DAKO (Carpinteria, CA) Autostainer
Universal Staining System, as previously described (Leach et al., 2002a). Rehydrated sections of
cultured explants were labeled for 1 h at 25°C with 5 μg/ml goat polyclonal antibody against
human recombinant HBEGF (R&D Systems) that recognizes both membrane and secreted forms
of the protein and 2.5 μg/ml antibody against cytokeratin (KRT7) (DAKO) specific for
trophoblast.

Controls were incubated with 10 μg/ml non-immune goat IgG (Jackson

Immunoresearch Laboratories, West Grove, PA). Tissues were then incubated 1 h at 25°C with
0.1 μg/ml rabbit anti-goat IgG (Jackson Immunoresearch).

Slides were viewed at 400 ×

magnification using a Leica (Wetzlar, Germany) DM IRB inverted microscope and imaged with
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spot camera. Trophoblast cells were labeled with monoclonal antibodies HSPA6 (Abcam)
diluted 1:400.

To visualize and quantify bound primary antibody, an Envision System

peroxidase anti-mouse/rabbit kit (DAKO) was used. Staining (grey level) was imaged using a
Leica DM IRB epifluorescence microscope, and images were captured using a Hamamatsu Orca
digital camera. Images were semi-quantified using SimplePCI (Hamamatsu) imaging software,
as previously described (Leach et al., 2012).
qPCR
RNA from HTR-8/SVneo cells was collected using the miRNeasy kit (Qiagen) that
included DNase treatment, according to the manufacturer’s protocol. RNA concentration was
determined using the NanoDrop spectrophotometer and purity was ascertained with a
microfluidic Bioanalyzer (Agilent Technologies - 2100 Electrophoresis Bioanalyzer Instrument).
RNA was used in subsequent qPCR (Bustin et al., 2009) analysis. Reverse transcription was
performed using the Quantitect Reverse Transcription kit (Qiagen), and qPCR for MMP2,
HBEGF and HSPA6 was conducted with the Quantitect SYBR Green PCR kit without UNG
(Qiagen), in a final volume of 25 μl. GAPDH and SDHA were used as housekeeping genes to
normalize the data. Semi-quantitative analysis was performed according to the ΔΔCt method
(Pfaffl, 2001). Primers for GAPDH, SDHA, HBEGF, MMP2 and HSPA6 were obtained from
Qiagen.
LongRNA (LnRNA) Library Prep for Next Generation Sequencing (NGS)
LnRNA was isolated using the miRNeasy mini kit (Qiagen). The RNA was quantified
and its purity assessed with an Agilent 2100 Electrophoresis Microfluidics Analyzer. RNA was
converted into an adapter-ligated cDNA library (Figure 2), using the Ovation & Encore Library
Preparation Kit (NuGen), according to the manufacturers protocol. Each cDNA sample was barcoded, and the resulting 12 libraries (three replicate libraries for each of the four O2 conditions)
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Figure 2. An example is shown for
the size distribution of an individual
library
using
the
Agilent
Bioanalyzer. A. Peak size (~250 bp)
B. Sample (S) size on gel projection,
as compared to a base pair (bp) ladder
(L).

were combined for NGS. Paired-end sequencing was performed for 50 cycles using the Illumina
HiSeq-2500 sequencer.
Data Alignment & Mapping
RNA sequencing data was first processed with demultiplexing software (Casava 1.8.2,
Illumina). It was then aligned to the human genome build HG19, and to the ribosomal sequences
18s and 28s, using bioinformatics tool Novoalign (Novocraft, 2010). Novoalign determined
unique alignments that were used to generate an average of 1000 reads per coding segment per
sample. The reads thus generated were converted into bed files and imported to the Genomatix
Genome Analyzer (GGA) (Genomatix Software GmbH). The GMS, using RNA-seq analysis,
generated data in the form of Reads per Kilobase of exon per Million fragments mapped
(RPKM) for 25,000 genes in the database.
Promoter Extraction
The Genomatix Genome Analyzer (GGA) MatInspector program (Cartharius et al., 2005)
was used to extract the promoter regions for the differentially regulated genes. MatInspector
utilizes a large library of matrix descriptions for transcription factor binding sites to locate
matches in DNA sequences. For the purpose of this study it was used to identify hypoxia
response elements (HRE) in differentially regulated genes.
Statistics
All statistics were performed with GraphPad Prism 6 software. One-way ANOVA with
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Student–Newman–Keuls post hoc comparisons was used to identify changes between controls
and treatments.

Two-way ANOVA was used for experiments with multiple groups.

Significance was defined as P < 0.05; all experiments were done three times (n=3) and data are
expressed as mean ± SD. For RNAseq data, adjusted p-values were calculated using BenjaminHochberg, and threshold was set at 0.05 to account for false discovery rate.
Results
Upregulation of MMP2 at low O2
Using a human MMP antibody array, we observed that relative expression of MMP2, but
not MMP9 or other MMPs, increased 1.7-fold in HTR-8/SVneo trophoblast cells cultured for 4
hrs at 2% O2 (Figure 3A), as compared to trophoblast cells cultured at 20 % O2. The specific
increase in expression of MMP2, and not MMP9, was confirmed by western blotting (Figure 3B
and Figure 4A &B). Cellular MMP2 was quantified temporally by ELISA in trophoblast cells
after shifting to 2% O2. The MMP2 concentration abruptly increased 164-fold (p<0.0001) after 2
hours of culture at 2% O2 (Figure 3C). These findings indicate that low O2 upregulates MMP2
prior to the observed increase in HBEGF, which occurs at 4 hrs (Armant et al., 2006).
Role of MMP2 in HBEGF upregulation
To determine whether MMP2 has a functional role in HBEGF regulation by O2, specific
inhibitors of MMP2 and MMP9 were supplemented in culture medium during manipulation of
O2 levels. HBEGF failed to accumulate in trophoblast cells cultured at 2% O2 for 4 h when
MMP2 was inhibited (Figure 3D). However, MMP9 inhibition had no effect on the normal
accumulation of HBEGF at low O2. A third inhibitor that targets both MMP2 and MMP9 (Inh.
2/9) also inhibited HBEGF accumulation.

Additionally, TUNEL assays showed increased

(p<0.0001) trophoblast cell death when both MMP2 and MMP9, or only MMP2, were inhibited
(Figure 3E).

Inhibition of only MMP9 produced apoptosis levels similar to control.

We
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conclude that MMP2, but not MMP9, either directly or indirectly, mediates the proteolytic
cleavage of proHBEGF, and subsequent survival signaling.

Figure 3. Upregulation of MMP2 at low O2, and its effects on HBEGF and cell survival. A.
Expression arrays for MMP-related proteins incubated with extracts of HTR-8/SVneo cells cultured at
20% (left) or 2% (right) O2. Arrows indicate elevated MMP2 at 2% compared to 20% O2. The key below
indicates the location of duplicate antibody probes for each protein according to the coordinates shown,
including both positive (Pos) and Negative (Neg) controls. B. Western blots of molecular weight
standards (Ladder), recombinant MMP2 or MMP9 (Control), and extracts of trophoblast cells cultured at
20% or 2% O2, as indicated. The upper blot was labeled with anti-MMP2, the middle blot was labeled
with anti-MMP9 and lower blot with anti-β-actin. C. MMP2 quantified by ELISA in trophoblast cells
cultured 0-4 h at 2% O2. D. HBEGF quantified by ELISA in trophoblast cells treated during culture for 4
h with the indicated MMP inhibitor or vehicle, and concentration of O2. E. Apoptosis was quantified in
trophoblast cells cultured as in D using the TUNEL assay. * p<0.05, compared to the control (0 h,
vehicle/20% O2).
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Figure 4. Western blots of
molecular
weight
standards
(Ladder), recombinant MMP2 or
MMP9 (Control), and extracts of
trophoblast cells cultured at 20% or
2% O2, as indicated. Blot A was
labeled with anti-MMP2, blot B was
labeled with anti-MMP9

MMP2 mRNA expression
To determine whether MMP2 is transcriptionally upregulated at low O2, its expression
was quantified by qPCR, using RNA extracted from HTR-8/SVneo cells cultured at 20 % and 2
% O2 for 1-4 hrs. Expression values, normalized to GAPDH, were calculated for both MMP2
(Figure 5A) and HBEGF (Figure 5B). MMP2 mRNA, like HBEGF message, did not change
(p=0.8) at 2% O2, suggesting that their proteins are both regulated post-transcriptionally.
Role of transcription in HBEGF upregulation
Trophoblast cells were cultured at 2% O2 with or without α-amanitin, an inhibitor of
RNA polymerase-II (Lindell et al., 1970; Stirpe and Fiume, 1967), to examine the role of de
novo transcription in the upregulation of HBEGF. MMP2 and HBEGF mRNA expression was
quantified by qPCR, using RNA extracted from HTR-8/SVneo cells cultured at 20 % and 2 % O2
for 6h, and with 5 µg/ml α-amanitin for 6h, 8h and 24h at 2 % O2.

Expression values,

normalized to GAPDH and SDHA, were calculated for both MMP2 (Figure 5C) and HBEGF
(Figure 5D). The presence of α-amanitin did not significantly alter the abundance of either
MMP2 (p=0.4454) or HBEGF (p=0.1357) transcripts in trophoblast cells cultured at 2% O2 for
up to 6h. However, a time-dependent decrease in both MMP2 and HBEGF mRNA abundance
was observed in α-amanitin-treated cells at 6-24 h that became significant at 24 h (p<0.05),
indicative of MMP2 and HBEGF mRNA turnover. Previous work done has shown that culturing
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HTR-8/SVneo cells at 2% O2 for 8h (Armant et al., 2006) and 24h (Kilburn et al., 2000)
increases proliferation of trophoblast cells, based on nuclear expression of the cell proliferation
marker, Ki-67. This suggests that the decrease in MMP2 and HBEGF mRNA after 24 h of αamanitin treatment is not due to increased apoptosis, as the cells are alive and proliferating.
Elevation of HBEGF protein after culture at 2% O2 for 6 h was abrogated in a dose-dependent
manner by α-amanitin, with maximal inhibition attained at 5 μg/ml (Figure 5E). Using ELISA,
we demonstrated that MMP2 was not only required for HBEGF upregulation (Figure 3D), but
that addition of rMMP2 was sufficient to increase (p<0.0001) HBEGF at 20% O2 to the same
extent as trophoblast culture at 2% O2 (Figure 3F). Furthermore, addition of rMMP2 rescued
(p<0.0001) HBEGF biosynthesis in the presence of α-amanitin at 2% O2 (Figure 5F), suggesting
that de novo transcription is required for MMP2 activity leading to the shedding and
accumulation of HBEGF.
CoCl2, a chemical mimic of hypoxia that stabilizes hypoxia inducible factor (HIF) by
inhibiting ubiquitination of HIF (Jiang et al., 1997), was used to examine its effect on HBEGF
regulation. At 20% O2, CoCl2 increased (p<0.0001) HBEGF levels. As expected, CoCl2 induced
accumulation of HIF1A and HIF2A, similar to the effect of low O2, according to western blotting
(Figure 6A, Figure 7A & B). The CoCl2-induced accumulation of HIF1A (Figure 6B) and
HIF2A (Figure 6C) was quantified by ELISA, establishing a significant increase comparable to
low O2.

α-Amanitin blocked the CoCl2-mediated increase in HBEGF (Figure 6D).

The

observed effects of α-amanitin on HBEGF accumulation suggest that transcription of genes,
likely regulated by HIF1A or HIF2A, is required to initiate MMP2 accumulation and HBEGF
shedding. Additionally, immunohistochemical staining of both HIF1A and HIF2A indicated the
localization of both HIF proteins to nucleus (indicated by arrows) as they accumulated after
exposure to low O2 for 0.5 to 1 h (Figure 7C).
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Figure 5. Expression of MMP2 and HBEGF at 2% O2 in HTR-8/SVneo cells. MMP2 (A, C) and
HBEGF (B, D) mRNA were measured by qPCR after culture for indicated time at 2% O2 (A, B) and
after culture with α-amanitin (2 µg/ml) at indicated time and O2 concentration (C, D). HBEGF protein
measured by ELISA in extracts of trophoblast cells cultured at the indicated concentrations of αamanitin and O2 (E) and in cellular extracts of trophoblast cells cultured for 4 h at either 20% or 2%
O2 in the presence of recombinant MMP2 (rMMP2) and α-amanitin, as indicated (F). *, p<0.05,
compared to no treatment/vehicle/20% O2, n=3.
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Figure 6. Expression of HIF proteins and HBEGF in the presence of CoCl2 in HTR-8/SVneo cells
A. Western blots of HIF1A (~ 93 kDa), HIF2A (~96 kDa) and β-actin (~45kDa) in lysates of cells treated
at 20% O2 or 2% O2 for 4 h, or at 20% O2 in the presence of 250 μM CoCl2 for 0.5 - 2 h, as indicated in
the Key below gel images. HIF1A (B) and HIF2A (C) protein measured by ELISA in extracts of
trophoblast cells treated at 20% O2 or 2% O2 for 4h, or at 20% O2 in the presence of 250 μM CoCl2 for
0.5 - 2 h. D. HBEGF protein measured by ELISA in extracts of trophoblast cells cultured at the indicated
concentrations of α-amanitin and CoCl2 at 20% O2. * p < 0.05 compared to no treatment control, n=3.
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Figure 7. Expression of HIF1A and HIF2A during altered O2 concentrations or simulated hypoxia
(CoCl2) in HTR-8/SVneo cells. Western blots showing the entire lanes for HIF1A (A, ~ 93 kDa) and
HIF2A (B, ~96 kDa) in TB cell lysates prepared after treatment at 20% O2 or 2% O2 for 4h, or at 20% O2
in the presence of 250 μM CoCl2 for 0.5 - 2 h, as indicated in the Key below gel images. C. TB cells
cultured at either 20%, or switched to 2% O2 for 0.5 or 1 h, as indicated. Cells were fixed and stained for
HIF1A (upper panel) and HIF2A (lower panel) using immunohistochemistry. Size bar, 50 µm. Arrows
indicate localization of HIF1A and HIF2A in nuclei.

Role of MAPKs in MMP2 upregulation
We previously showed that upregulation of HBEGF at low O2 requires MAPK signaling
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(Jessmon et al., 2010). MMP2 was quantified by ELISA in extracts of trophoblast cells cultured
at 2% O2 for 4 hours, with or without specific inhibitors of ERK, p38 and JNK, or the
corresponding inactive structural analogs (Table 1). Inhibitors of MAPKs had no effect on the
increased MMP2 expression at 2% O2, suggesting that the upregulation of MMP2 is independent
of MAPK, and that MAPK signaling most likely functions exclusively downstream of ERBB
activation.
Table 1. MMP2 upregulation is independent of MAPKs
Treatment
% O2
20
Vehicle
2
Vehicle
2
U 0126/ERK inhibitor
2
U0124/ERK Negative control
2
JNK inhibitor
2
JNK Negative control
2
SB203580 P38 inhibitor
2
SB 202474 P38 Negative control
2
All 3 inhibitors
2
All 3 neg. controls

MMP2 (ng/ml)
0.03 ± 0.03
7.27 ± 0.74 *
6.07 ± 0.55 *
7.40 ± 0.66 *
5.44 ± 1.98 *
6.53 ± 1.23 *
6.17 ± 0.87 *
7.15 ± 089 *
5.86 ± 1.51 *
6.34 ± 0.68 *

* p<0.0001

Identification of differentially expressed transcripts
Transcripts differentially expressed in trophoblast cells at the two O2 levels were
identified, using a non-biased NGS approach. RNA-seq analysis using the GGA revealed a total
of 9 upregulated (Table 2) and 120 downregulated genes (Table 3) after 1 hr of exposure to 2%
O2 (Figure 8A). Of the 9 upregulated genes, HSPA6 was the most dramatically upregulated
(870-fold) (Table 3), and the only gene that remained elevated at 2 h (Figure 8B) and 4 h (Figure
8C). The increase in HSPA6 expression at 2% O2 was validated using qPCR (18 fold, p<0.0001)
and western blotting (2.3 fold, p<0.05) (Figure 8D, E). Extraction of the promoter region using
the GGA MatInspector (Cartharius et al., 2005) program revealed two overlapping HRE’s 2.4

33
kbp upstream of the 5’-most HSPA6 transcriptional start site (Figure 9), suggesting that HSPA6
could operate downstream of hypoxia to regulate MMP2 and HBEGF biosynthesis at low O2.
Interestingly, as expected RNAseq data showed that although HBEGF and HIF1A were not
differentially regulated yet their transcripts were present and showed no change in RPKM values
after shifting trophoblast cells from 20% to 2% O2. Surprisingly, MMP2 was not detected
possibly due to low abundance of its transcript, or a problem in the software used to map it to the
human genome.
Table 2. Upregulated transcripts from RNASeq analysis
Gene Symbol
Gene ID
Log 2 fold change
0h vs 1h
0h vs 2h

0h vs 4h

HSPA6

3310

6.771

7.78

6.55

FAP

2191

5.188

--

--

LOC100131607

100131607

5.043

--

--

SNORA5A

654319

4.826

--

--

RPS16P5

647190

4.794

--

--

ZNF319

57567

4.564

--

--

IL8

3576

4.435

--

--

VTRNA1-3

56662

4.039

--

--

CLK1

1195

3.687

--

--

Log 2 fold change
0h vs 2h

0h vs 4h

Table 3. Downregulated transcripts from RNASeq analysis
Gene Symbol

Gene ID
0h vs 1h

ATG9A

79065

-9.071

-9.071

-9.028

LOC100506361

100506361

-8.257

-8.969

-8.885

WHSC2

7469

-8.225

-8.470

-8.737

CCNF

899

-7.736

-8.450

-8.403

RBPMS2

348093

-7.713

-8.306

-8.368

RXRA

6256

-7.617

-8.265

-8.312

PGPEP1

54858

-7.594

-8.234

-8.260

TONSL

4796

-7.569

-8.173

-8.228

RUSC1

23623

-7.518

-8.126

-8.215

SOLH

6650

-7.518

-8.122

-7.867

RPS6KA4

8986

-7.426

-8.015

-7.855

CLEC16A

23274

-7.41

-7.914

-7.831
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ZFPL1

7542

-7.365

-7.611

-7.764

CAPG

822

-7.336

-7.595

-7.727

SFSWAP

6433

-7.323

-7.570

-7.687

TMEM184B

25829

-7.293

-7.474

-7.657

BAD

572

-7.262

-7.367

-7.496

SUN2

25777

-6.818

-7.381

-7.534

CDC42EP1

11135

-6.494

-7.293

-7.521

PKMYT1

9088

-6.466

-7.293

-7.465

SCAMP5

192683

-5.818

-7.237

-7.345

WDR6

11180

-5.782

-7.173

-7.147

SMG6

23293

-5.677

-7.033

-6.976

ESPL1

9700

-5.659

-7.020

-6.914

DPYSL2

1808

-5.581

-6.953

-6.879

SEC24D

9871

-5.5

-6.753

-6.791

EPHB4

2050

-5.498

-6.747

-6.704

SEC16A

9919

-5.443

-6.742

-6.685

PLCD3

113026

-5.309

-6.701

-6.648

GLI2

2736

-5.282

-6.688

-6.603

ATXN2L

11273

-5.227

-6.606

-6.518

POLR2A

5430

-5.14

-6.601

-6.488

SLC19A1

6573

-5.13

-6.521

-6.322

RANBP10

57610

-5.095

-6.520

-6.248

SYNPO

11346

-5.043

-6.506

-6.241

SMTN

6525

-5.042

-6.380

-6.188

GYS1

2997

-5

-6.297

-6.148

PTP4A3

11156

-4.964

-6.284

-6.083

RAI1

10743

-4.955

-6.237

-5.994

POM121

9883

-4.935

-6.212

-5.966

PCNXL3

399909

-4.863

-6.146

-5.955

PPDPF

79144

-4.82

-6.113

-5.949

EIF4G1

1981

-4.755

-6.089

-5.933

ZNF646

9726

-4.755

-6.039

-5.911

NUMBL

9253

-4.667

-6.031

-5.837

GPR56

9289

-4.665

-6.026

-5.834

SPSB1

80176

-4.65

-6.435

-5.810

SLC48A1

55652

-4.641

-5.915

-5.745

SHKBP1

92799

-4.616

-5.880

-5.668

ZNF703

80139

-4.585

-5.832

-5.637

ORAI1

84876

-4.582

-5.659

-5.568

TAPBP

6892

-4.58

-5.599

-5.544

RNFT2

84900

-4.547

-5.457

-5.534

SOX13

9580

-4.53

-5.450

-5.490

35
TMEM131

23505

-4.528

-5.387

-5.482

PLXNB2

23654

-4.511

-5.379

-5.475

CREB3L2

64764

-4.477

-5.163

-5.452

ALG3

10195

-4.426

-5.110

-5.438

MEN1

4221

-4.379

-5.045

-5.333

TTLL4

9654

-4.327

-4.781

-5.305

LLGL1

3996

-4.325

-4.759

-5.302

CTTN

2017

-4.323

-4.755

-5.276

BCL9L

283149

-4.311

-4.673

-5.193

ATN1

1822

-4.286

-4.584

-5.070

MYADM

91663

-4.265

-4.528

-5.040

PHF1

5252

-4.229

-4.506

-4.993

BCAR1

9564

-4.228

-4.432

-4.975

MLXIP

22877

-4.219

-4.383

-4.966

PRRC2B

84726

-4.219

-4.357

-4.962

RNF31

55072

-4.213

-4.304

-4.895

ZNF777

27153

-4.153

-4.233

-4.845

SRRM2

23524

-4.088

-4.232

-4.825

CBX6

23466

-4.084

-4.194

-4.796

RAB1B

81876

-4.069

-4.189

-4.789

COL6A1

1291

-4.035

-4.174

-4.740

WBP2

23558

-4.032

-4.141

-4.707

FOSL2

2355

-3.988

-4.044

-4.704

PRRC2A

7916

-3.983

-4.033

-4.665

TRIM26

7726

-3.962

-4.032

-4.640

COTL1

23406

-3.959

-4.020

-4.522

DBN1

1627

-3.933

-3.989

-4.498

SEPN1

57190

-3.913

-3.964

-4.494

PFKP

5214

-3.907

-3.900

-4.482

RNF220

55182

-3.898

-3.936

-4.438

RAVER1

125950

-3.894

-3.897

-4.422

COL1A1

1277

-3.88

-3.866

-4.249

TMEM109

79073

-3.875

-3.823

-4.239

ACOT7

11332

-3.875

-3.799

-4.226

SDC1

6382

-3.859

-3.781

-4.201

NRSN2

80023

-3.856

-3.754

-4.161

BGN

633

-3.842

-3.700

-4.109

CIZ1

25792

-3.79

-3.677

-4.030

DAG1

1605

-3.789

-3.643

-4.009

NUP214

8021

-3.772

-3.642

-3.918

CYB5R3

1727

-3.771

-3.615

-3.883

NPRL3

8131

-3.762

-3.577

-3.864
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COL4A2

1284

-3.748

-3.552

-3.811

SLC7A5

8140

-3.722

-3.482

-3.794

SRCAP

10847

-3.707

-3.460

-3.782

FOSL1

8061

-3.691

-3.443

-3.773

CYP2S1

29785

-3.676

-3.404

-3.762

PLEC

5339

-3.662

-3.405

-3.733

GIT1

28964

-3.657

-3.365

-3.722

NACC1

112939

-3.595

-3.363

-3.710

C20orf112

140688

-3.569

-3.348

-3.672

MAP2K7

5609

-3.487

-3.341

-3.638

C16orf57

79650

-3.475

-3.299

-3.425

ZFP36L1

677

-3.447

-3.234

-3.400

SLC25A23

79085

-3.426

-3.203

-3.395

LDOC1

23641

-3.409

-3.190

-3.235

AP2A1

160

-3.402

-3.180

-3.214

APEX2

27301

-3.357

-3.136

-3.196

PLOD1

5351

-3.312

-3.109

-3.176

EHMT2

10919

-3.268

-3.069

-3.150

SCAMP2

10066

-3.263

-3.037

-3.132

HEATR2

54919

-3.252

-2.956

-3.086

LRRC8A

56262

-3.246

-2.920

-3.079

ZNF574

64763

-3.207

-2.916

-3.006

PTRF

284119

-3.196

-2.892

-2.945

PPARD

5467

-3.026

-2.789

-2.582

MDH2

4191

-2.983

-2.7329

-2.564
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Figure 8. Transcriptome graph analysis of trophoblast cells exposed to 2% O2. A-C. Abundance of
transcripts compared using GGA work station between cells cultured at 2% O2 for 0 h (x-axis) and 1 h (A,
y-axis), 2 h (B, y-axis) or 4 h (C, y-axis). Unchanged transcripts are indicated in blue, upregulated
transcripts are red, and downregulated transcripts are black. HSPA6 (red triangle) was the most highly
upregulated mRNA, and only transcript upregulated at 2 h and 4 h. D. HSPA6 mRNA was measured by
qPCR in trophoblast cells cultured for indicated time at 2% O2. E. Western blots of HSPA6 (~ 70 kDa)
and β-actin (~43 kDa) in lysates of trophoblast cells cultured for indicated time at 2% O2.
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Figure 9. Transcriptome analysis of trophoblast cells exposed to 2% O2. MatInspector on the GGA
work station was used to extract promoter regions of upregulated genes between cells cultured at 2% O2
for 0 h and 1 h to identify HRE sites (Blue boxes). Splice variants (*) also shown.
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HSP70 function in MMP2 and HBEGF upregulation
Inhibition of HSP70 with a pharmacological inhibitor, VER 155008 (Schlecht et al.,
2013), in trophoblast cells cultured at 2% O2 caused a dose-dependent decrease in MMP2
(Figure 10A) and HBEGF (Figure 10B). VER 155008 acts by binding to the nucleotide binding
site of HSP70 thereby arresting the nucleotide binding domain in a half open conformation.
VER 155008 acts as an ATP-competitive inhibitor that prevents allosteric control between the

Figure 10. Regulation of MMP2, HBEGF and cell survival by HSP70. HSP70 was inhibited using
the pharmacological inhibitor VER 155008 during culture of HTR-8/SVneo cells for 4 h at 20% or 2%
O2. At 2% O2, HSP70 inhibition caused a dose-dependent decrease in both MMP2 (A) and HBEGF (B),
measured by immunohistochemistry, and concomitantly increased cell death (C), measured by TUNEL.
Cells cultured at 20% O2 were unaffected. D. ELISA for HBEGF in cellular extracts of trophoblast cells
cultured for 4 h at either 20% or 2% O2 in the presence of recombinant MMP2 (rMMP2) and HSP70
inhibitor (VER 155008), as indicated. * p<0.05, compared to vehicle/20% O2.
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nucleotide binding domain and the substrate binding domain (Schlecht et al., 2013). TUNEL
assays showed increased (p<0.0001) trophoblast cell death with HSP70 inhibition (Figure 10C),
suggesting that survival at 2% O2, through upregulation of MMP2 and HBEGF, requires HSPA6
activity.

Using ELISA, we demonstrated that MMP2 was not only required for HBEGF

upregulation (Figure 3D), but that addition of rMMP2 was sufficient to increase (p<0.0001)
HBEGF at 20% O2 to the same extent as trophoblast culture at 2% O2 (Figure 10D).
Furthermore, addition of rMMP2 rescued (p<0.0001) HBEGF biosynthesis in the presence of
HSP70 inhibitor at 2% O2 (Figure 10D). These results demonstrate that upregulation of MMP2
requires HSPA6 (HSP70B’) activity, while upregulation of HBEGF requires only shedding
mediated by MMP2.
Regulation of MMP2 in first trimester explants
Using immunohistochemistry and ELISA, it was confirmed that HSP70 inhibitor
prevents the upregulation of MMP2 (Figure 11A, B) and HBEGF (Figure 8C, D) in first
trimester explants cultured at 2% O2 similar to the observed expression affects in HTR-8/SVneo
(Figure 10). In addition, rMMP2 alone increased (p<0.0001) HBEGF at 20% O2, and rescued
(p<0.0001) HBEGF upregulation at 2% O2 during treatment with HSP70 inhibitor (Figure 11C,
D). Cell death assays showed increased (p<0.05) cell death during HSP70 inhibition that was
rescued (p<0.05) by rMMP2 (Figure 11E, F), suggesting that survival at 2% O2, through
upregulation of MMP2 and HBEGF, requires HSPA6 activity.
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Figure 11. Regulation of MMP2 in first trimester chorionic villous explants. First trimester villous
explants cultured for 6 h at either 20% or 2% O2 in the presence of recombinant MMP2 (rMMP2) and
VER 155008 (HSP70 inh.), as indicated, were stained for MMP2 & Cytokeratin (KRT7) (A), HBEGF &
KRT7 (C) with counterstaining with Hematoxylin. Healthy nuclei counterstained with Hematoxylin
appear blue and dual staining with DAPI and TUNEL (E), using immunofluorescence microscopy. Size
bars indicating 10 µm are shown in A, C and 100 µm as shown in E. Cell extracts were assayed by
ELISA for MMP2 (B) and HBEGF (D), as well as for cell death by TUNEL (F). *, p<0.0001 in B and
D, p<0.05 in F, compared to vehicle/20% O2, n=3

Discussion
The regulation of HBEGF signaling during implantation and placentation is critical for
trophoblast survival and invasion (Jessmon et al., 2009; Lim and Dey, 2009). An autocrine,
post-transcriptional mechanism induced at low O2 upregulates HBEGF synthesis and secretion,
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providing an important survival factor during early gestation (Armant et al., 2006; Jessmon et al.,
2009). The present study provides evidence that a transcriptional event is required to initiate
HBEGF shedding downstream of HIF signaling. In seeking a metalloproteinase responsible for
HBEGF shedding, a human MMP antibody array, verified by western blot and ELISA,
implicated a protease cascade that includes MMP2.

A functional role for MMP2 in the

accumulation of HBEGF was established using a specific inhibitor. The increase in apoptosis
observed by using another specific inhibitor for both MMP2 and MMP9 was greater, but not
significantly different than the increase by MMP2 inhibition alone. The increase found with
MMP2/9 inhibition could be additive; however, that is unlikely because apoptosis was
unaffected by inhibition of MMP9 alone, compared to control. MMP2 mRNA concentration was
unaltered by reduced O2, suggesting that it was regulated post-transcriptionally. Transcriptomic
analysis identified HSPA6, a member of the HSP70 family, as a potential regulator upstream of
MMP2. Using an inhibitor of HSP70 and exogenous rMMP2, evidence was obtained supporting
a mechanism wherein low O2 concentrations, as experienced by trophoblast cells during the first
10 weeks of placentation, induce HIF-mediated transcription of HSP70, a chaperone that directly
or indirectly facilitates MMP2 accumulation. MMP2, in turn, appears to participate in a protease
cascade that sheds HBEGF from the cell surface (Hitchon et al., 2002; Mohammad et al., 2010).
The production of sHBEGF initiates autocrine signaling through its cognate receptors, EGFR
and ERBB4 which activates its biosynthesis from constitutively-expressed, but latent HBEGF
mRNA (Figure 12).

43

Figure 12. Proposed Mechanism. Low (2%) O2 stabilizes cytoplasmic HIF1A and HIF2A (1) that
accumulate and translocate to the nucleus (2) where they dimerize to HIF1B and bind to hypoxia
response elements (HRE) in the regulatory regions of target genes, including HSPA6/HSP70B’ (3).
HSP70 regulates the accumulation of activated MMP2 at the cell surface (4), which is required and
sufficient for shedding (5) of the extracellular domain of proHBEGF. The released sHBEGF binds (6) to
its receptors, ERBB1 and ERBB4, through its EGF-like domain and to heparan sulfate proteoglycans
(HSPG) through its heparin-binding domain. ERBB downstream signaling activates MAPKs (7) required
for biosynthesis of proHBEGF from the pool of HBEGF mRNA (8). HBEGF autocrine signaling thereby
increases HBEGF secretion to achieve extracellular HBEGF concentrations (>1 nM) sufficient to inhibit
apoptosis at 2% O2.

Supplementation with HBEGF and other EGF family members such as EGF or TGFα has
little effect on proliferation rates, but is highly effective at converting trophoblast cells to an
invasive phenotype (Leach et al., 2004). The extensive expression of HBEGF in trophoblast
cells, particularly within extravillous populations (Leach et al., 2002a), could be vital for their
invasive activities during the establishment of pregnancy and physiological conversion of spiral
arteries. Therefore, it has been established that HBEGF regulates trophoblast survival and
invasion, two crucial functions that are compromised in pregnancies complicated by
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preeclampsia (Brosens et al., 1972; DiFederico et al., 1999). HBEGF and other components of
the EGF signaling system are disrupted in placentas of women with preeclampsia (Armant et al.,
2015; Leach et al., 2002a). Trophoblast invasion is shallow in preeclampsia, possibly due to a
lack of HBEGF-induced cell migration and a rise in apoptosis, exacerbated by reduced
cytoprotection. The increased oxidative damage to trophoblast cells (Redman and Sargent,
2005) and the decrease in HBEGF in preeclamptic placentas is consistent with the hypothesis
that HBEGF is an important survival factor throughout gestation. In this study we are focused at
the role of HBEGF in cell survival to better understand the underlying mechanism.
Jessmon et. al showed that HBEGF activates ERK, p38 and JNK in human trophoblast
cells, and treatment with specific inhibitors indicated that hypoxia upregulates HBEGF
biosynthesis through any one of the three examined MAPKs (Armant et al., 2006; Jessmon et al.,
2010). However, it was unclear whether this MAPK pathway was functional upstream or
downstream of HBEGF shedding. Therefore, MMP2 was quantified in human trophoblast cells
cultured at 2% O2 with specific inhibitors of ERK, p38 and JNK. These inhibitors did not
influence the upregulation of MMP2 at low O2, suggesting that the MAPKs function only
downstream of HBEGF signaling through the ERBB1/4 tyrosine kinases in human trophoblast
cells, as indicated in Figure 12.
MMP2 was not among the genes that were transcriptionally regulated at low O2, but
nevertheless appears to participate in a proteolytic cascade that culminates in HBEGF shedding.
Studies of early placentation suggest that MMP2 is important in trophoblast invasion (StaunRam et al., 2004). Interestingly, very low O2 (0.1%) increases MMP2 mRNA levels 1.7-fold in
trophoblast cells isolated from first trimester placentae (Onogi et al., 2011), which was not found
in our study. However, culture at 2% O2 could differ significantly from 0.1% O2, and account
for the different outcomes. Using specific inhibitors and rMMP2, we showed that MMP2, but
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not HBEGF, is regulated by HSP70. It appears that HSP70 stabilizes either MMP2 or a protein
regulating its accumulation at the cell surface for shedding of HBEGF.
Although both MMP2 and HBEGF appear to be regulated by O2 post-transcriptionally,
HBEGF upregulation by low O2 or CoCl2 was blocked by -amanitin, suggesting the
requirement for transcription. HIF proteins are stabilized at low O2 (Wang and Semenza, 1993),
and activate transcription of targeted genes by interaction with specific HREs in the gene
promoters (Semenza, 2003), along with transcriptional coactivators to form an initiation complex
(Lisy and Peet, 2008). We suspected that either HIF1A or HIF2A could be involved in the
response of trophoblast cells to low O2, based on their accumulation under the influence of CoCl2
or 2% O2, which was previously reported in JEG3 choriocarcinoma cells (Park et al., 2014).
Interestingly, the transcriptome analysis revealed HSPA6/HSP70B’ as the most highly
upregulated gene at 1-4 h, while no changes occurred in transcripts of metalloproteinases.
Extraction of the HSPA6 promoter revealed two overlapping HREs on the sense and anti-sense
strands. HREs also appeared in the promoters of the eight other mRNAs that increased 1 h after
exposure of trophoblast cells to low O2. Interestingly, microarray analysis identifies only 216
genes have HRE sites in the human genome (Ortiz-Barahona et al., 2010).

In rabbit

chondrocytes and JEG3 cells increased expression of HIF1A under hypoxia (2%) or simulated
hypoxia (CoCl2) resulted in an increases in HSP70 expression, which is was ablated by HIF1A
inhibition or knockdown (Park et al., 2014; Tsuchida et al., 2014). These data suggest that
HSP70 transcription is induced by HIF1A signaling.
Induction of heat shock proteins (HSPs) in response to cellular stress has been proposed
as a potential strategy of eukaryotic cells to combat lethal conditions (Ananthan et al., 1986;
Goff and Goldberg, 1985; Parsell and Sauer, 1989). Within the HSP family, HSP70 functions in
the recovery of cells from stress, and in guarding against further insults (Fulda et al., 2010).
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HSP70 is a multigene family that includes the stress-inducible members HSPA6 and
HSPA1A/HSP70-1 (Schwarz et al., 2003; Tavaria et al., 1996). HSP70 protects stressed cells by
recognizing nascent polypeptides, unstructured regions of protein, and exposed hydrophobic
stretches of amino acid (Nollen and Morimoto, 2002). The binding of exposed hydrophobic
residues in unfolded or partially folded proteins is regulated by ATP-hydrolysis-induced
conformational changes in the ATPase domain of HSP70, which is stimulated by co-chaperones
(Nollen and Morimoto, 2002). HSP70 is transcribed in response to stress due to activation of
heat shock transcription factor (HSF) (Abravaya et al., 1992). Abravaya et.al proposed a model
suggesting that physiological stress creates misfolded proteins that compete with HSF for
binding to HSP70, resulting in release of transcriptionally active, DNA-binding HSF to induce
transcription of heat shock genes. Baird et.al has shown that this HSF-mediated transcription is
increased under low O2 due to direct binding of HIF1A to its HRE on the HSF intron (Baird et
al., 2006). These reports are consistent with a mechanism wherein HSP70 transcription is
mediated by HSF or HIF1A at low O2 in trophoblast cells.
HSP70 forms a molecular chaperone complex with HSP90, another highly conserved and
essential HSP family member (Pratt et al., 2015; Pratt and Toft, 2003).

This molecular

chaperone complex is dependent on the hydrolysis of ATP, and ADP/ATP exchange, and is
mediated by association with HOP (Hsp70/Hsp90-organising protein)/STIP1 (stress-induced
phosphoprotein 1) (Carrigan et al., 2006; Chen and Smith, 1998). The HSP70/HSP90 molecular
chaperone complex, optimized by HOP, coordinates interactions that ensure folding and
conformational regulation of proteins under stress (Hernandez et al., 2002; Wegele et al., 2004).
RNAi knockdown of HOP in pancreatic cancer cells decreases expression of MMP2 (Walsh et
al., 2011). Additionally, inhibition or depletion of HSP70 in the breast cancer cell line, MA-MB231, decreases cell migration and invasion due to a lack of MMP2 activation (Sims et al., 2011).
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This suggests that molecular relationships between HSPs, various signaling proteins, and partner
proteins mediate the integrity of signal transduction pathways (Nollen and Morimoto, 2002).
Our data further supports the role for HSP70 in mediating MMP2 function, which is required in
trophoblast cells for HBEGF survival signaling.
The signaling cascade delineated in the present study (Figure 12) could influence
multiple physiological processes that play a key role in placentation.

There is substantial

evidence to support that HBEGF expression is altered in preeclampsia, and that its protein levels
are decreased in preeclamptic placentas (Armant et al., 2015; Leach et al., 2002a). MMP2
belongs to a family of extracellular matrix-remodeling enzymes that have been implicated in the
regulation of vasculogenesis, which is disrupted in placental insufficiency disorders, such as
preeclampsia. There is compelling evidence that MMP2, but not MMP9, increases in women
who subsequently develop preeclampsia (Eleuterio et al., 2015; Montagnana et al., 2009; Myers
et al., 2005; Narumiya et al., 2001). HSP70 also appears to be altered in adverse pregnancies. In
a pilot study, higher levels of HSP70 were reported in patients with early onset of severe PE
(Jirecek et al., 2002; Yung et al., 2014). Fukushima et.al reported that serum levels of HSP70
were constant throughout normal pregnancy, but increased significantly in women with
preeclampsia (Fukushima et al., 2005; Molvarec et al., 2006) or preterm delivery (Fukushima et
al., 2005). Increased circulating HSP70 in preeclamptic patients could be due to systemic
inflammation as a result of disease and increased oxidative stress (Ekambaram, 2011; Molvarec
et al., 2009). In term preeclamptic placentas, HIF1A and HSP70 are both elevated and, localized
prominently in syncytiotrophoblasts and villous endothelial cells (Park et al., 2014). In another
study of HSP70 in term placentas, both mRNA and protein increased in women with
preeclampsia and intrauterine growth restriction (Liu et al., 2008). However, there has been no
information reported on the expression or role of placental HSP70 in the first trimester prior to
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this study.
Using an established trophoblast cell line and a villous explant model, we have
established a role for HSPA6 (HSP70B’), a HIF-regulated gene, in the regulation of MMP2
required for HBEGF shedding at low O2. These findings suggest that trophoblast survival in the
low O2 environment during early pregnancy requires this signaling pathway. Disruption of any
component during the first trimester could compromise trophoblast survival and function,
leading to placental insufficiency and the resulting obstetrical complications of pregnancy.
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CHAPTER 3 - REGULATION OF HBEGF BY MICRO-RNA FOR SURVIVAL OF
DEVELOPING HUMAN TROPHOBLAST CELLS
Abstract
The growth factor HBEGF is upregulated post-transcriptionally in the low O2
environment of the human placenta during the first 10 weeks of pregnancy. We have examined
the possible roles of HBEGF turnover and micro-RNA (miRNA) signaling in its regulation by O2
in human first trimester trophoblast cells. HTR-8/SVneo trophoblast cells were cultured at 2% or
20% O2 with vehicle, 10 µg/ml cyclohexamide, 1 µg/ml lactocystin, 100 µg/ml MG132, or
siRNA to knockdown DGCR8 in the microprocessor. HBEGF, DGCR8, and β–actin were
examined by western blotting. HBEGF was quantified by ELISA. Protein turnover studies using
cyclohexamide demonstrated faster HBEGF degradation at 20 % O2 than 2% O2 mediated by the
proteasome. However, proteasome inhibitors were insufficient to initiate HBEGF accumulation
at 20% O2.

Trophoblast cells were transfected with a dual luciferase reporter construct

(psiCHECK-2) containing no insert (control), the HBEGF 3’ untranslated region (3’UTR), or
sub-regions of the 3’UTR. Reporter activity relative to empty vector demonstrated that the intact
HBEGF 3’ UTR inhibited expression (0.26), while fragments containing only its flanking
regions increased reporter activity (3.15; 3.43). RNA was extracted from trophoblast cells
cultured at 2% O2 for 0-4 h for next-generation sequencing to quantify miRNAs. Although, no
differential expression of any miRNAs was found in trophoblast cells, nevertheless, HBEGF
upregulation at 2% O2 was blocked when the miRNA-processing protein DGCR8 was silenced,
suggesting a role for miRNA. Our findings suggest involvement of flanking regions of the
3’UTR in activating HBEGF protein synthesis in response to 2% O2, possibly through a miRNAmediated mechanism.
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Introduction
The epidermal growth factor (EGF) family member, heparin binding EGF-like growth
factor, (HBEGF), is present in the uterus at the time of embryo implantation (Leach et al., 1999;
Yoo et al., 1997). In addition, its expression in trophoblast cells of the invading placenta
indicates its central role in early implantation and subsequent placentation (Leach et al., 2002a).
Since, the placenta is not fully oxygenated until after the 10th week of pregnancy, placentation
proceeds in a low O2 (2%) environment. In vitro work has demonstrated that HBEGF protein
levels are upregulated in human first trimester trophoblast cells at low (2%) O2 (Armant et al.,
2006). Furthermore, HBEGF protects trophoblast cells from apoptosis, and promotes their
invasion (Leach et al., 2004; Leach et al., 2008). Preeclampsia, in which trophoblast invasion is
reduced and apoptosis elevated, is characterized by in vivo reduction of HBEGF expression, as
well as disruption of and other regulatory components of EGF signaling system in TB cells
(Armant et al., 2015; Leach et al., 2002b). A mechanism for the regulation of HBEGF by O2 in
TB cells is beginning to emerge, based on recent studies of a first trimester TB cell line.
Transmembrane HBEGF cleavage in response to low O2 initiates autocrine signaling that
increases HBEGF levels to a concentration that inhibits apoptosis (Armant et al., 2006). The
autocrine upregulation of HBEGF requires activation of its cognate receptors (ERBB1 and
ERBB4), and downstream signaling through any one of three MAPK pathways initiated by
MAPK 1/3, MAPK14 or MAPK8 (Jessmon et al., 2010). Previous work has demonstrated that
HBEGF is not transcriptionally regulated by O2, although its protein levels increase by over 100fold at low O2 (Armant et al., 2006). HBEGF mRNA levels are high and remain unchanged by
exposure to low O2. It remains to be determined that at what point downstream of HBEGF
shedding HBEGF accumulation is regulated by this autocrine mechanism.
Regulation of transcription and translation can be disparate processes, depending on the
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gene and cellular context (DiFederico et al., 1999; Koritzinsky et al., 2005). The abundance of
specific proteins can be regulated post-translationally by altering their turnover rates (Kristensen
et al., 2013). Proteins with fast turnover rates are generally characterized as low abundance
(Boisvert et al., 2012; Schwanhausser et al., 2011), intrinsically unstructured (Gsponer et al.,
2008; Prakash et al., 2004), or aggregation prone (De Baets et al., 2011; Gsponer and Babu,
2012), and are mostly involved in signal transduction and transcriptional activation (Boisvert et
al., 2012; Legewie et al., 2008; Yen et al., 2008). Alternatively, HBEGF downstream signaling
could be involved in inhibiting its protein turnover to increase its abundance through its
autocrine signaling (Figure 13). Certain proteins can be regulated by either stabilization (Zhao et
al., 2008) or destabilization (Baudouin-Legros et al., 2005; Phelps et al., 2006) of their mRNA.
A prior study has shown that HBEGF mRNA is stabilized in HeLa cells exposed to a
chemotherapeutic agent (Sorensen et al., 2006). Because HBEGF transcript levels are not altered
by O2 fluctuation (Armant et al., 2006), we hypothesized that mRNA translation is a factor
contributing to its regulation. There is evidence that microRNAs (miRNA) could directly or
indirectly regulate protein expression by increasing translational rates (Baek et al., 2008; Selbach
et al., 2008).
MicroRNAs are ~22 nt endogenous small RNA species that primarily target the 3’
untranslated region (3’UTR) of mRNA transcripts, and are well known for their roles in
suppressing translation or inducing degradation of mRNA (Kim and Nam, 2006; Pillai et al.,
2007). DGCR8 is a gene within the “DiGeorge syndrome chromosomal region (DGCR)” at
human chromosome 22q11 (Shiohama et al., 2003). DGCR8 combines with Drosha to form a
stable microprocessor, or pri-miRNA processing complex (Gregory et al., 2004; Han et al., 2004;
Landthaler et al., 2004). MicroRNAs are transcribed as primary miRNA transcripts in the
nucleus by RNA polymerase II and are subsequently processed by the microprocessor into
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shorter pre-miRNA hairpin precursors. The pre-miRNAs are exported into the cytoplasm and
processed into their mature ~22 nt form by dicer (Bartel, 2004).

Mature miRNAs are

incorporated into RNA-induced silencing complexes (RISCs) or miRNPs (miRNA
ribonucleoproteins) where miRNAs target mRNAs by binding with perfect complementarity to a
conserved 6-8 nt seed region in the 3’UTR. MicroRNAs have the unique capacity to bind a
specific target transcript and, due to imperfect base pairing at nucleotides 10-11, inhibit
translation without inducing degradation of the mRNA (Bartel, 2004; Filipowicz et al., 2008;
Pillai et al., 2007). A miRNA-mediated mechanism could be responsible for the translational
regulation of HBEGF by O2 concentrations.
Specific miRNAs are expressed in placental tissue (Barad et al., 2004; Maccani and
Marsit, 2009; Mouillet et al., 2011) and trophoblast cells (Donker et al., 2007; Spruce et al.,
2010). When introduced into cariocarcinoma cell cultures, miRNAs target functional proteins.
Mir-152 targets HLA-G in JEG3 cells (Zhu et al., 2010), miR-34a targets Notch1 and Jagged1 in
HeLa and JAR cells (Pang et al., 2010), and miR-199b targets SET (protein phosphatase 2A
inhibitor) in BeWo and JAR cells (Chao et al., 2010). Donker et al. (Donker et al., 2007)
demonstrated in primary trophoblast from term placenta that the miRNP machinery is present in
cells cultured for 24-72 h at 20% or 2% O2, and silences MED1 (Mediator complex subunit 1)
expression through differential regulation of miRNAs (Mouillet et al., 2010).

Regulated

expression of miRNAs that target HBEGF mRNA could likewise provide evidence that its
translational regulation at 2% O2 is mediated by miRNAs.
In this study we have tested whether the regulation of HBEGF protein is mediated
through its turnover rate, or if other post-transcriptional mechanisms are operative. Specifically,
we examined reporter expression under control of the 3’UTR of HBEGF, the role of differential
miRNA expression in the trophoblast cells exposed to reduced O2, and the effect of global
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miRNA silencing by DGCR8 knockdown. Our findings suggest a role for miRNA in the
upregulation of HBEGF at 2% O2 rather than its suppression at 20% O2. We suggest that the
RISC becomes altered to enable translation from constitutively expressed HBEGF message
downstream of HBEGF signaling at 2% O2.
Materials and Methods
Cell Culture and Treatments
The first trimester human cytotrophoblast cell line HTR-8/SVneo (Graham et al., 1993)
was cultured at either 20% O2 or 2% O2 as previously described (Leach et al., 2004; Leach et al.,
2008). Cells were cultured for the indicated times in 10 µg/ml cyclohexamide to block de novo
translation (Sigma-Aldrich), 1 µg/ml lactocystin or 100 µg/ml MG132 to inhibit the proteasome
(EMD Biosciences). The HTR-8/SVneo cell line retains important characteristics of primary
cultures of human first trimester cytotrophoblast cells (Kilburn et al., 2000), making it a suitable
model for this study. This cell line expresses the TB specific marker KRT7. When grown on
Matrigel, HTR-8/SVneo cells expresses another TB specific marker HLA-G, and expression of
integrin alpha 1 is upregulated, while alpha 6 is downregulated. The expression of KRT7, βhCG and HLA-G as well as lack of Vimentin is routinely checked and cells are maintained at
passages 30-50.
Western Blotting
Western blots were performed as previously described (Kilburn et al., 2000). Cellular
lysates were lysed in SDS sample buffer containing 5% β-mercaptoethanol, run on precast 4%20% Tris-HCl gradient gels (BioRad), and transferred to nitrocellulose membranes. Monoclonal
mouse antibodies against DGCR8 (Proteintech) and GAPDH (Ambion) were diluted in 5% milk
dissolved in TTBS to 0.3 µg/ml and 1 µg/ml, respectively. A polyclonal antibody against
HBEGF (R&D Systems) was diluted to 0.2 µg/ml in 5 mg/ml BSA in TTBS.
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ELISA
The HBEGF DuoSet ELISA Development kit (R&D systems) was used, as previously
described (Armant et al., 2006; Leach et al., 2008). The optical density of the final reaction
product was determined at 450 nm, using a programmable multiplate spectrophotometer (Power
Wave Workstation; Bio-Tek Instruments) with automatic wavelength correction.
Generation of 3’UTR Luciferase Reporter Vectors
Regions of the HBEGF 3’UTR were amplified by PCR. Restriction sites for XhoI and
NotI were added to forward and reverse primers (IDT DNA), respectively. 3’UTR regions
(Figure 14) amplified by the primers and the expected amplicon sizes are listed in Table 4. The
PCR amplified 3’UTR regions were cloned into the psiCheck-2 vector (Promega), in which two
luciferase genes (Firefly and Renilla) driven by separate promoters are present. HBEGF 3’UTR
inserts were cloned into a region immediately following the Renilla luciferase gene, which serves
as the reporter, while the Firefly luciferase gene is an internal control. After isolating RNA from
trophoblast cells (miRNeasy, Qiagen), cDNA was generated using the Omniscript Reverse
Transcription kit (Qiagen). HBEGF 3’UTR fragments were amplified by endpoint PCR, using
HotstarTaq Plus Master Mix kit (Qiagen), according to the manufacturer’s instructions. In a total
reaction volume of 50 µl, 0.5 µM of each primer and 50 ng of cDNA were combined. PCR
products were processed using Wizard SV Gel and PCR Clean-up Kit (Promega). Cleaned
amplicons and the PsiCheck2 vector (1 µg each) were digested with both XhoI and NotI
restriction enzymes (Promega) for 1 h at 37ºC in a thermal cycler, followed by a 15 min 70ºC
inactivation step.

Amplified 3’UTR fragments and PsiCheck2 vector were combined and

ligated, using Promega’s LigaFast Rapid DNA Ligation System. To verify ligation, 1 µl of
ligated product was amplified by PCR, using primers that bind outside of the PsiCheck2 vector’s
multiple restriction site, as indicated in Table 4. The primers listed were used in various
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combinations to target different regions of HBEGF 3’UTR.
Table 4. Primer sequence for amplification of HBEGF 3’UTR and vector sequencing.
Forward Primers

Sequence

HBEGF 3’UTR
HBEGF 3’UTR
HBEGF 3’UTR
HBEGF 3’UTR
PsiCheck-2 vector

AAACTCGAGGGAGGTTATGATGTGGGAAAATGA
AAACTCGAGCCTTTGCCACAAAGCTAGGA
AAACTCGAGTTGCCTAGGCGATTTTGTCT
AAACTCGAGAACAGGGAACATTGGAGCTG
AGGACGCTCCAGATGAAATG

Reverse Primers

Sequence

HBEGF 3’UTR
HBEGF 3’UTR
HBEGF 3’UTR
HBEGF 3’UTR

AAAGCGGCCGCAGATCCCTTGGTGGTACT
AAAGCGGCCGCCAGGAAATTGCCAAAGTA
AAAGCGGCCGCCCAAGTTAACCCCTACATCCTG
AAAGCGGCCGCATGAACCAGGTTTGGAAATACA
CAAACCCTAACCACCGCTTA

PsiCheck-2 vector

Target Site on
HBEGF mRNA

844
1644
1829
2137
Target Site on
HBEGF mRNA

1363
1603
1778
2315

Bacterial Transformations
One microliter of the ligation reaction mixture or empty PsiCheck2 vector was placed on
ice, combined with 50 µl of JM109 bacteria (Promega) and heat shocked.

Bacteria were

incubated on an LB Agar plate containing AMP-100, X-GAL-80, IPTG-50 (Teknova) overnight
at 37ºC. Colonies were grown and expanded in 3 ml of LB broth (Becton, Dickinson & Co.)
containing 100 µg/ml of Ampicillin. Bacterial lysates were prepared and amplified by PCR with
primers in Table 1 to select colonies that displayed a correctly-sized insert. Vectors were
isolated using the Wizard Plus SV Miniprep kits (Promega), and 100 ng were used for
transfection reactions.

Vectors were sequenced using the same primers utilized to verify

ligation, and aligned to the HBEGF mRNA sequence (PUBMED sequence NM_0001945.2)
using Geneious (Kearse et al., 2012).
Transfection and Luciferase Assay
HTR-8/SVneo cells were grown to 75 % confluence and cultured for an additional 24 hr
in 1 ml serum-free media (DMEM/F-12 with 5 mg/ml BSA) containing 3 µl of FuGene-6 and 1
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µl of vector (100 ng). The cells were lysed in 500 µl 1X passive lysis buffer (Promega). Lysates
(20 µl) was used in each dual luciferase reaction, conducted according to the manufacturer’s
protocol (Dual Luciferase Reporter Kit, Promega). Negative controls containing untransfected
cells were included. Each sample received 100 µl of LARII reagent, and was read after adding
100 µl Stop & Glo reagent (Promega) using a Veritas microplate luminometer (Turner
Biosystems). Renilla measurements were normalized to Firefly measurements. Each transfection
experiment was repeated at least 3 times.
Library Preparation for NGS
Trophoblast cells maintained at 20% O2 were cultured at 2% O2 for 0-4 hrs and RNA was
collected.

For RNA-seq, both long RNA and small RNA (sRNA) were isolated with the

miRNeasy mini kit (Qiagen). The long RNA fraction was used for transcriptomic analysis in
Chapter 2. The sRNA fraction was quantified and its purity assessed, using an Agilent 2100
Electrophoresis Microfluidics Analyzer.

A sRNA digital gene expression library was

constructed by converting RNA into an adapter-ligated cDNA library, using a ScriptSeq Miner
(Epicentre) and following the manufacturer’s protocol. Each cDNA sample was bar-coded and
the resulting 12 cDNA libraries (3 replicates for each O2 concentration) were combined for
sequencing on Illumina’s Genome Analyzer II sequencer at the Wayne State University Applied
Genomics Technology Center.
Sequencing Data analysis
Demultiplexing was performed using configure BclToFastq.pl script (CASAVA-1.8.2;
Illumina Inc.) with default parameters for quality and index identification. The sequencing data
was aligned to the human genome build (HG19) and to the ribosomal sequences 18S and 28S
using Genomatix mapping station (GMS). The GMS generated tsv.files were exported to the
Genomatix genome analyzer and subjected to the miRNA expression analysis tool to identify
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differentially expressed miRNAs.
DGCR8 Knockdown
HTR-8/SVneo cells were tested for toxicity due to NeoFX transfection reagent (Ambion),
using the Multitox-Fluor Multiplex Cytoxocity Assay Kit (Promega) to determine an optimal
concentration for transfection, which was 0.75 µl of NeoFX reagent per well in a 96-well plate,
(<10% toxicity after 48 hrs). Cells were transfected in a 96-well plate (5,000 per well) for 48 hr
with various concentrations of three siRNAs (s29061, s29062, s29063; Life Technologies) that
target DGCR8.

Controls included no transfection, treatment with transfection agent only,

transfection with a negative control siRNA and a GAPDH siRNA. Cells were fixed with icecold methanol for 10 min, permeabilized with 0.1% Triton-X100 for 15 min, stained overnight
with primary antibody against DGCR8 (Santa Cruz Biotechnology, Inc.) at 4ºC, incubated for 1
hr at room temperature with an anti-mouse/anti-rabbit labeled polymer (DAKO EnVision Dual
Link), and visualized with DAB. Based on preliminary experiments, 50 nM siRNA was chosen
for DGCR8 knock down.
qPCR
RNA from HTR-8/SVneo cells was collected using the miRNeasy kit (Qiagen),
according to the manufacturer’s protocol.

RNA concentration was determined using the

NanoDrop spectrophotometer and purity was ascertained with a microfluidic Bioanalyzer
(Agilent Technologies - 2100 Electrophoresis Bioanalyzer Instrument).

RNA was used in

subsequent qPCR (Bustin et al., 2009) analysis. Reverse transcription was performed using the
Quantitect Reverse Transcription kit (Qiagen), and qPCR for HBEGF was conducted with the
Quantitect SYBR Green PCR kit without UNG (Qiagen), in a final volume of 25 μl. GAPDH
was used as a housekeeping gene to normalize the data.

Semi-quantitative analysis was

performed according to the ΔΔCt method (Pfaffl, 2001). Primers for GAPDH and HBEGF were
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obtained from Qiagen.
Statistics
All experiments were repeated at least 3 times and reported as mean ± SEM. Statistical
significance was determined at p<0.05 by ANOVA, Student-Newman-Keuls tests and Dunnett ttest using SPSS version 12.0 statistics software (SPSS).
Results
HBEGF regulation by protein degradation
The observed increase in HBEGF protein levels at low O2 could reflect a decrease in
protein turnover rate at 2% O2. HBEGF protein levels were elevated by culture at 2% O2 for 6 h
and cultured for an additional 2 hours with cyclohexamide to arrest protein synthesis. HBEGF
levels remained unchanged (Figure 13 A), indicating a very low turnover rate. In contrast, cells
shifted to 20% O2 after 6 h at 2% O2 showed a marked destabilization of HBEGF protein, which
declined significantly within 15 min (Figure 13 B). HBEGF degradation was abrogated if cells
were concomitantly treated with the proteasome inhibitors MG132 or lactocystin after shifting
cells to 20% O2, suggesting that HBEGF turnover requires the proteasome. However, HBEGF
protein did not increase at 20% O2 when cells were treated with proteasome inhibitors (data not
shown), suggesting that stabilization of HBEGF degradation is insufficient for its accumulation
at 20% O2, and that its accumulation at 2% O2 requires activation of its translational from
mRNA. These finding indicate that destabilization by proteolysis through the proteasome clears
HBEGF during reoxygenation.
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A

Figure 13. Effect of O2 concentration on HBEGF
stability. HTR8S/Vneo cells were cultured for 6 h at
2% O2, allowing HBEGF protein to accumulate.
Afterwards, cells were (A) exposed to cyclohexamide
for up to 2 h in the absence or (B) presence of either 1
µg/ml lactocystin (white circle) or 100 µg/ml MG132
(triangle). Cell lysates were collected at the indicated
times and HBEGF protein levels quantified by
ELISA. * p < 0.05 according to ANOVA and
Student-Newman-Keuls t-tests.

B

Regulation by the HBEGF 3’UTR
The differential regulation of HBEGF synthesis by O2 in human trophoblast cells could
be the result of translational suppression at 20% O2, or activation of protein synthesis from its
mRNA at 2% O2 under the direction of its large (1455bp) 3’UTR, a region of mRNA known to
be involved in transcript stability (Mignone et al., 2002). To determine whether the 3’UTR of
HBEGF can control translation, a PsiCheck-2 luciferase reporter with 3’ inserts of the entire
HBEGF 3’UTR or its subdomains was prepared and transfected into trophoblast cells cultured at
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20% O2. The presence of certain portions of the HBEGF 3’UTR altered Renilla Luciferase
production, as compared to an empty vector control (Figure 14). A vector containing the fulllength 3’UTR (844-2315) significantly (p=0.008) repressed reporter activity, as did
vectorscontaining the 5’ subdomain (844-1778; p=0.031) or 3’ subdomain (1644-2315;
p=0.019). In contrast, the 134 bp region overlapped by the two larger domains did not regulate
reporter activity. Vectors containing regions 844-1603, 1644-1778, and 1829-2315 were also not
active. Vectors containing either the 5’ (844-1363) or 3’ (2137-2315) flanking regions of the
3’UTR upregulated Renilla luciferase activity at both 20% O2 and 2% O2 (p<0.001 for both).
The vectors containing the two flanking regions more significantly upregulated reporter at 20%
O2 as compared to 2% O2 (t-test, p=0.022 and p<0.001, respectively).

Based on these

Figure 14. Translational regulation by HBEGF 3’UTR. Dual luciferase assays used constructs containing
the indicated sequences of the HBEGF mRNA inserted 3’ to Renilla luciferase. The left panel shows activities
of the Renilla luciferase normalized to a constitutive firefly luciferase. N=3. *, p<0.05 vs empty vector control
(blue bar), ANOVA with Dunnett t-test. Right panel shows the locations of the inserts in colors indicating their
effect on translation; yellow, neutral; red, suppression; green, activation. A scale in base pairs is shown below.
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observations, it appears that the two flanking domains of the 3’UTR increase translational
activity in isolation from the central 3’UTR regions, while the presence of regions from 1363bp1644bp and 1778bp-1829bp instigated translational suppression. These data are consistent with
two opposing activities within the 3’UTR that respectively activate and suppress translation from
the HBEGF transcript.
Next generation sequencing to identify differentially expressed miRNAs
To determine if HBEGF translation is regulated in response to O2 by differentially
expressed miRNAs that interact with its 3’UTR, expression of miRNAs was examined globally
by NGS. Trophoblast cells cultured at 20% O2 were exposed to 2% O2 for 0, 1, 2 and 4 h, and

A

C

B

Figure 15. Effect of O2 on miRNA expression by
next generation sequencing: Log-log comparisons
of RPKM values for 2556 miRNAs
in
HTR8/SVneo cells after transfer from 20% O2 to
2% O2 for 0 h (x-axis, A-C) and y-axis 1 h (A), 2 h
(B) or 4 h (C). No miRNAs deviated significantly
from a straight line with slope of 1.

barcoded libraries were constructed for NGS. The software analyzed a total of 2556 miRNAs
based on the HG19. A log-log plot of RPKM values comparing 0 h to later time points (Figure
15), and statistical analysis by the Genomatix genome analyzer software, revealed that no
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miRNAs were differentially expressed. These findings suggest that if a mechanism involving
miRNAs regulates HBEGF translation, it does not do so through changes in the expression of the
miRNAs.
Global inhibition of miRNA processing
We further examined the potential role of miRNA in regulating HBEGF, using siRNA to
silence DGCR8, which should globally suppress miRNA processing and deplete all miRNA
(Landthaler et al., 2004). DGCR8 was knocked down in HTR-8/SVneo cells by transfection for
48 h with siRNA. Controls included no transfection, treatment with transfection reagents only,
and transfection with either a negative control siRNA or a GAPDH siRNA. Culture was either
continued for 4 h at either 20% O2, or shifted to 2% O2. Western blots for DGCR8 and toxicity
assays were used to optimize conditions for knockdown (Figure 16A, B). DGCR8 was greatly
reduced in cells transfected with 50 nM of the targeting siRNA, but not in control treatments.
Unexpectedly, HBEGF expression did not increase when DGCR8 was knocked down at 20% O2
(Figure 16C), suggesting that HBEGF expression was not repressed by miRNA at high O2.
Repression of translation by miRNA often occurs through degradation of message (Wilczynska
and Bushell, 2015). However, HBEGF mRNA was unchanged after DGCR8 knockdown and
unaffected by O2 concentration (Table 5). Surprisingly, the upregulation of HBEGF at 2% O2
was inhibited in the DGCR8 knockdown compared to controls (Figure 16D). These results were
verified by ELISA to quantify HBEGF, which demonstrated levels near 0.01 pg/μg in all
treatments at 20% O2 (Figure 16E). At 2% O2, HBEGF levels rose to 5 pg/μg (range 4.2-6.4) in
all controls, while cells transfected with 50 nM DGCR8 siRNA contained only 0.88 ± 0.22 pg/μg
HBEGF (Figure 16F). These findings indicate that HBEGF expression was not repressed by
miRNA at high O2, and further suggest that miRNA is required for increased translation of
HBEGF at 2% O2.
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Table 5. HBEGF mRNA in HTR-8/SVneo cells with or without (Control) exposure to
DGCR8 siRNA measured by qPCR*
2% O2
20% O2
Control

DGCR8 siRNA 50nM

Control

DGCR8 siRNA 50nM

1.3 ± 0.26

0.92 ± 0.27

1.07 ± 0.30

1.39 ± 0.39

*Relative expression of HBEGF mRNA normalized to GAPDH mRNA. Mean ± SE, n = 3.

Figure 16. Effect of DGCR8 Knockdown on regulation of HBEGF by O2. Western blots of DGCR8
in lysates of HTR-8/SVneo cells treated for 48 hr with (A) 5 nM or 10 nM of three different DGCR8
siRNA and (B) different pairings of the three siRNA (5nM). C-F. DGCR8 (~120kDa) , HBEGF
(~22kDa) and -actin (~45kDa) were assessed in lysates of HTR-8/SVneo cells (control), cells treated
with transfection reagent only, or cells transfected with GAPDH siRNA, 50 nM negative control siRNA,
and 5 nM and 50 nM DGCR8 siRNA. After 48 hrs, culture was continued for 4 hrs at 20% O2 (C, E) or
2% O2 (D, F). Lysates were assayed by western blot (C, D) or an ELISA for HBEGF (E, F). Untreated
trophoblast cells and trophoblast cells containing transfection reagent alone served as Control. *,
p<0.005, compared to Control.

Discussion
The present study demonstrates the complexity of HBEGF upregulation, and suggests the
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potential role of miRNAs. Blocking HBEGF degradation with proteasome inhibitors failed to
instigate accumulation of HBEGF in trophoblast cells cultured at 20% O2, suggesting that the
upregulation of HBEGF at low O2 is not due solely to decreased HBEGF turnover, but requires
increased translation of abundant HBEGF mRNA. HBEGF turnover was indeed strikingly faster
at 20% than at 2% O2, which could facilitate clearance of the protein during reoxygenation.
Given the lack of transcriptional regulation (Armant et al., 2006), it was hypothesized
that HBEGF could be regulated translationally by its large (1461 bp) 3’UTR.

Luciferase

reporters have been used to assess translational regulation by 3’UTRs (Pang et al., 2009) and
provided evidence here that cloned regions of the HBEGF 3’UTR regulate its translation with
domain-specific stimulatory or inhibitory activities.

Others have examined translational

suppression by miRNA with cloned 3’UTR regions by transfecting with an additional vector that
contains target miRNA in HEK293 cells (Jiao et al., 2010) and HTR-8/SVneo cells (Mouillet et
al., 2010). The methodology that we chose is advantageous because it more closely recapitulates
in vivo conditions by relying upon endogenous miRNA and translational machinery. Although
there was no effect of changing O2 concentrations, the flanking regions of the 3’UTR (844-1363
and 2317-2315) strongly upregulated luciferase activity, suggesting that these domains could
have a role in elevating HBEGF translation at 2% O2. In contrast, regions towards the center of
the 3’UTR (1363-1603 and 1778-2315) repressed luciferase production, and are likely
responsible for the overall repressive effect of the complete 3’UTR sequence. Luciferase assays
showed that discrete regions of the 3’UTR are sufficient to differentially regulate HBEGF.
An unbiased NGS approach failed to find miRNAs that are differentially expressed at
20% and 2% O2. Therefore, HBEGF was apparently not regulated by changes in the levels of
miRNAs that interact with its transcript, but other components of the RISC interacting with
miRNAs could be involved. The requirement for miRNA was further examined by blocking
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miRNA synthesis in a DGCR8 knockdown experiment, realizing that it could interfere with other
unrelated critical cellular processes. Suh et al used Dgcr8 knockout mice to distinguish the
effects of miRNA and endogenous siRNA during oocyte maturation and preimplantation
development, comparing the effects on development and mRNA expression to oocytes and
embryos deficient in Dicer (Suh et al., 2010). During treatment with DGCR8 siRNA, the low
expression of HBEGF at 20% O2 persisted. However, HBEGF protein failed to increase at 2%
O2, suggesting that miRNA is linked to increased HBEGF translation in either a positive or
indirect manor at 2% O2 rather than through suppression at 20% O2. This is consistent with the
observation that HBEGF mRNA expression was unchanged by DGCR8 knockdown at either O2
concentration. Hence, miRNA could be responsible for facilitating the upregulation of HBEGF
through changes in other components of the RISC at low O2 that increase the influence of the
flanking regions of the 3’UTR (844-1363 and 2137-2315), or reduce the influence of the
repressive central domains. The regulatory activity of the RISC can be affected by structural
changes in the 3’UTR, such as shortening. For example, 3’ UTR shortening can occur due to
cleavage of the alternative poly(A) sites on the 3’UTR of mRNA, and this can lead to changes in
protein translation efficiency, mRNA stability, or mRNA localization (Fabian et al., 2010). To
see if this structural change was present in HBEGF 3’UTR, we examined the RNAseq data
obtained in Chapter 2. However, due to low sequencing depth we found no clear evidence of
HBEGF 3’UTR shortening.
Alternatively, miRNAs or other regulatory factors that bind regions outside the 3’UTR
(for example, to the 5’UTR) could accelerate translation of HBEGF at 2% O2. There is evidence
that miR-10a binds to the 5’oligopyrimidine tract motif in the 5’UTR of ribosomal proteins in
neural U87 cells and mediates translational upregulation (Orom et al., 2008). MiR-122 targets
the 5’non-coding region of the hepatitis C viral genome to positively regulate accumulation of
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viral RNA (Jopling et al., 2005) through requisite occupation of two miR-122 binding sites in
hepatic cells (Jopling et al., 2008). Hence, miRNA or other regulatory factors that bind regions
outside the 3’UTR could integrate with regions in the 3’UTR to induce translation at 2% O2.
In the absence of a change in miRNA profile, HBEGF translation could be controlled by
other components of the RISC, including regulatory proteins activated downstream of MAPK
signaling, which is required for HBEGF upregulation at 2% O2 (Jessmon et al., 2010). Iwasaki
et. al found that loading of sRNA duplexes into the RISC complex requires HSP70/HSP90
chaperones activity (Iwasaki et al., 2010). We find in trophoblast cells that HSP70 transcription
is induced at low O2 (Jain et al., unpublished). Alternatively, there is evidence that the stability
of argonaute 2 (AGO2) in the RISC is enhanced by EGFR/ERBB1 through MAPK signaling in
cancer cell line MDA-MB-231 (Adams et al., 2009). EGFR induces phosphorylation of Y393 in
AGO2 to inhibit miRNA maturation, leading to tumor cell survival (Shen et al., 2013). Using
mass spectrometry, multiple phosphorylation sites have been identified in AGO2 from HEK293
cells (Rudel et al., 2011). Phosphorylation of Y529 in the RNA-binding pocket results in
inefficient binding of sRNA to the protein, suggesting a mechanism for the alternate binding and
release of miRNAs. Additionally, studies in Hela cells demonstrate that phosphorylation of
AGO2 by AKT serine/threonine kinase 3 (AKT3) and MK2 at S387 upregulates miRNAmediated translational repression of endogenous miRNA targets (Horman et al., 2013). Some
RNAs can displace miRNAs from their target mRNAs. An example is competing endogenous
RNA (ceRNA) (Salmena et al., 2011) or the recently described circular RNA (circRNA)
(Hentze and Preiss, 2013), where the RNAs not only manifest themselves in the sequestration of
miRNAs, but also act through the direct or indirect binding of RNA-binding proteins.
Genes other than HBEGF are also translationally regulated by O2. For example, low O2
increases ATF4 protein, but doesn’t affect its mRNA, in hippocampal neurons (Yukawa et al.,
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1999). In addition, chemically-induced endoplasmic reticulum (ER) stress, comparable to effect
of low O2, shifts ATF4 mRNA from monoribosomes to polyribosomes, indicating that its
preexistent mRNA pool is inefficiently translated until cells experience ER stress. This shift to
polyribosomes was dependent on the presence of ER-resident eIF2alpha kinase/PERK,
suggesting that eukaryotic initiation factor 2A (EIF2A) is phosphorylated prior to translation of
ATF4 (Koumenis et al., 2002).
Additional studies are necessary to fully understand the mechanism controlling HBEGF
autocrine upregulation. We have presented evidence that the RISC is a key site of regulation;
therefore, proteomic analysis of the RISC could identify components that are altered in response
to HBEGF downstream signaling. Future studies involving Chip Seq (Park, 2009) could help to
elucidate the role of RISC and its components in controlling the HBEGF autocrine loop.
Alternatively, motif-binding prediction tools such as Scansite (Obenauer et al., 2003) would
help to elucidate the interaction of other molecules with the HEGF 3’UTR that could play a
critical role in HBEGF upregulation. The significance of this mechanism in vivo is unclear,
because this investigation was conducted in a trophoblast cell line. However, we have found that
HBEGF is indeed upregulated at low O2 in villous explants (Chapter 2, Figure 12).

The

development of an animal model to experimentally investigate the proposed mechanism would
be useful to clarify understanding of HBEGF regulation by O2 in vivo.
The present study demonstrates that HBEGF is post-transcriptionally regulated by O2
through a mechanism involving interactions of miRNAs with its 3'UTR. Luciferase assays
identified discrete regions of the 3’UTR that differentially regulate HBEGF translation. A role
for miRNA was suggested by knocking down the miRNA-processing protein, DGCR8.
Although no differentially expressed miRNAs were found, it can be speculated that miRNAs are
required for translation of HBEGF, but not for its repression at low O2. The regulation of
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HBEGF through a targeted mechanism that increases its translation rate, putatively involving
miRNA and the RISC, appears to be uncommon based on a paucity of similar reports in the
literature.

The elucidation of this complex regulatory mechanism could provide important

insights into trophoblast survival during early placentation, and its disruption in pregnancies with
developmental pathologies.
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CHAPTER 4 - FETAL GENOME PROFILING AT FIVE WEEKS OF GESTATION
AFTER NONINVASIVE ISOLATION OF TROPHOBLAST CELLS FROM THE
ENDOCERVICAL CANAL
Abstract
Single gene mutations account for over 6000 diseases, 10% of all pediatric hospital
admissions, and 20% of infant deaths. Down syndrome and other aneuploidies occur in over
0.2% of births worldwide and are on the rise due to advanced reproductive age. Birth defects of
genetic origin can be diagnosed in utero after invasive extraction of fetal tissues, while
noninvasive testing with circulating cell-free fetal DNA is limited by a low fetal DNA fraction.
Both modalities are unavailable until the end of the first trimester. We have isolated intact
trophoblast cells from Papanicolaou smears collected non-invasively at 5-19 weeks of gestation
for next-generation sequencing of fetal DNA. Matched maternal, placental and fetal samples
(n=20), were profiled by multiplex targeted DNA sequencing of 59 short tandem repeat and 94
single nucleotide polymorphism sites across all 24 chromosomes. The data revealed a fetal DNA
fractions of 85-99.9% with 100% correct fetal haplotyping. This noninvasive platform is capable
of providing comprehensive fetal genomic profiling as early as 5 weeks of gestation.
Introduction
Current models for studying placental biology include ex vivo models like explant culture
(Genbacev et al., 1992) and in vivo models involving cell lines (Orendi et al., 2011). Although
these models mimic the physiology of trophoblast cells, yet they are a mixed population of cells.
Based on the research over decades, the current notion is that the disruption of function of extravillous trophoblast (EVT) cells leads to placental insufficiency and the root cause lying in the
first trimester of pregnancy. Both the ex vivo and in vivo models not only fail to represent a pure
EVT population but are only based end point analysis. Therefore, there is a need of a platform to
assess the EVT cells in ongoing pregnancies to better understand their pathophysiology and their
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role in the progression of disease. Trophoblast retrieval and isolation from the cervix (TRIC) is
an innovative and transformative technology to safely assess these cells (Bolnick et al., 2014).
Fetal cells isolated by TRIC can provide the conceptual foundation to develop a reliable
approach for interrogation of the pathophysiological status of pregnancy in vivo that will enhance
research on the human placenta, and the ability to diagnosis perinatal disease. Although it
appears that cells obtained by TRIC are indeed of fetal origin based on lineage marker
expression and Y chromosome detection by fluorescent in situ hybridization (FISH) when a male
fetus is present (Bolnick et al., 2014), we rigorously tested this assumption by comparing the
genotypes of maternal-fetal cell pairs from twenty pregnancies examined by TRIC in the study
presented here.
Prenatal testing for genetic disorders is currently performed invasively with a limited, but
definite, risk using amniocentesis (earliest at 12 weeks) or chorionic villous sampling (CVS)
(earliest at 9 weeks) (Mujezinovic and Alfirevic, 2007; Wapner, 2005).

In addition,

preimplantation genetic screening is available as an adjunct to in vitro fertilization (Sermon et
al., 2004). In the past five decades, tremendous efforts have been made to develop reliable,
noninvasive, early and safe prenatal testing techniques, using intact fetal erythrocytes, cell-free
fetal DNA, and endocervical fetal cells (Chitty and Bianchi, 2013; Gil et al., 2015; Rodeck et al.,
1995). These approaches have identified chromosomal abnormalities, sex-linked diseases, and
RHD genotype in fetuses. In addition, prenatal screening of cell-free fetal DNA in maternal
blood (earliest at 8 weeks) has been implemented clinically with some restrictions.

The

technology relies on fetal DNA fragments that accumulate and rapidly turn over in maternal
blood, with analysis by massively parallel sequencing to distinguish fetal from maternal
haplotypes (Gil et al., 2015; Wapner, 2005; Wong and Lo, 2016). However, the small fetal
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fraction (4-10% at 10 weeks of gestation) and fragmentation of degrading DNA (146 bp) in the
circulation limit its reliability for probing a broad range of significant genetic anomalies (Wang
et al., 2013; Wong and Lo, 2016). The fetal fraction of DNA rises steadily with gestational age,
but must exceed 4% for accurate and reliable assessment of specific trisomies (Wang et al.,
2013). It is particularly challenging with a low fetal fraction to detect a fetal haplotype that is
over-represented in the maternal fraction of DNA, such as a male fetus at risk for an X-linked
disorder (Wong and Lo, 2016). Digital polymerase chain reaction (PCR) assays can detect
autosomal recessive sickle cell anemia (Barrett et al., 2012) and X-linked hemophilia (Tsui et al.,
2011), but rely on exact quantification of the fetal fraction, which can be problematic in the first
trimester due to the overwhelming amount of co-purifying maternal DNA. The American
College of Obstetricians and Gynecologists recommends that positive cell-free DNA results
should be verified by the invasive tests, CVS and amniocentesis, which are considered diagnostic
(2015).
A simple, reliable, and safe approach to fully interrogate the intact fetal genome early in
the first trimester of pregnancy at single nucleotide resolution currently does not exist. To
address and close this gap, we developed a straightforward alternative that uses a Papanicolaou
(Pap) smear to capture intact fetal cells in numbers sufficient for next generation sequencing as
early as 5 weeks of gestation. Fetal cells with a placenta (trophoblast) -like cellular phenotype
are naturally shed from the conceptus into the reproductive tract by a poorly understood
mechanism (Adinolfi and Sherlock, 1997; Imudia et al., 2010; Shettles, 1971). Until now their
presence offered little benefit for noninvasive testing due to low cell recovery, and a 2000-fold
excess of maternal cells and DNA in endocervical specimens (Imudia et al., 2009). We first
reported that fetal cells can be purified to near homogeneity by TRIC (average 99%), using Pap
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smears safely collected during early pregnancy with a nylon cytobrush from the lower segment
of the endocervical canal (Bolnick et al., 2014). Importantly, in contrast to cell free fetal DNA
(Wang et al., 2013), we showed that provision of fetal cells by TRIC is unaffected by gestational
age between 5 and 20 weeks of gestation, or by maternal obesity (Fritz et al., 2015b), thus
providing a robust source of fetal DNA during a period of pregnancy when it is most useful
clinically.
Here, we report the development of a DNA isolation and genotyping protocol that
provides a high fetal fraction from cervical fetal cells obtained by TRIC during ongoing
pregnancies at 5-19 weeks of gestation (Figure 16). Fetal DNA was assessed in twenty
specimens using multiplex targeted sequencing to distinguish it from maternal DNA, based on
profiling of 153 short tandem repeat (STR) and single nucleotide polymorphism (SNP) sites
across the entire genome.
Materials and Methods
Patient selection
The institutional review board of Wayne State University approved this study, and each
participating patient provided informed written consent. Pregnant women between 5-19 weeks
of gestation and undergoing pregnancy termination were recruited. The patients were counseled
for collection of endocervical specimens and placenta at the Safe and Sound for Women Clinic
in Las Vegas, NV and the Northland Family Planning Centers of Michigan.
Isolation of endocervical fetal trophoblast cells
Endocervical sampling was performed as described previously (Imudia et al., 2009).
Endocervical cells were immediately fixed post the Pap smear procedure, using a ThinPrep kit
(Hologic, Marlborough, MA) to preserve cells, proteins, and nucleic acids. Trophoblast cells
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were isolated from each specimen using TRIC (Bolnick et al., 2014).

Briefly, cells were

centrifuged and re-suspended in 10 mL phosphate buffered saline (PBS), washing them three
times. After a final resuspension in 1.5 mL PBS, anti-HLA-G-coated magnetic nanoparticles
were added and incubated overnight at 4°C with mixing. The non-bound (maternal) cells were
collected after magnetic immobilization of HLA-G-positive cells, which were recovered after
three washings in PBS. The HLA-G-positive (fetal) cells were assessed by immunofluorescence
microscopy for expression of β-hCG, and the percentage of labeled cells was determined.
Fluorescence in situ hybridization (FISH)
Isolated fetal cells were mounted on slides and probed for X and Y chromosomes by
FISH at the Detroit Medical Center Cytogenetics Laboratory, using the DYZ1 satellite III on the
Y chromosome, and the DXZ1 alpha satellite on the X chromosome as fluorescently-labeled
probes (Abbott Molecular).

Nuclei were counterstained with DAPI and scored for each

chromosome to quantify cells that were XX or XY.
Targeted sequencing
DNA was obtained from fetal and maternal cells isolated by TRIC and tissue from the
corresponding placenta. Targeted sequencing was performed using pregnancies with both male
and female fetuses (N=20).
Nuclear isolation and DNA extraction
Targeted sequencing was performed for 94 SNPs and 56 STRs listed in Table 6 after
digestion of exogenous DNA. Fetal and maternal cells obtained by TRIC were dropped on slides
and allowed to dry. Prior to DNA extraction, the slides were immersed in pepsin solution (0.01g
in 100 ml 0.1N HCl) for 11 mins, followed by a PBS wash for 5 mins to remove cell membranes
and contaminating maternal DNA fragments.

Exogenous or circulating DNA was further
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eliminated from the glass-bound nuclei by adding 10 µL of washed, immobilized DNase (DNase
I, immobilized on matrix F7M, MoBiTec, Goettingen, Germany) onto the pepsin-treated slides,
Table 6: List of SNP’s and STR’s targeted by FORENSEQ.
Sr.No
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

SNP name
rs1490413
rs560681
rs1294331
rs10495407
rs891700
rs1413212
rs876724
rs1109037
rs993934
rs12997453
rs907100
rs1357617
rs4364205
rs2399332
rs1355366
rs6444724
rs2046361
rs279844
rs6811238
rs1979255
rs717302
rs159606
rs13182883
rs251934
rs338882
rs13218440
rs1336071
rs214955
rs727811
rs6955448
rs917118
rs321198
rs737681
rs763869
rs10092491
rs2056277
rs4606077
rs1015250
rs7041158
rs1463729
rs1360288
rs10776839
rs826472
rs735155
rs3780962
rs740598
rs964681

Sr.No
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94

SNP name
rs1498553
rs901398
rs10488710
rs2076848
rs2107612
rs2269355
rs2920816
rs2111980
rs10773760
rs1335873
rs1886510
rs1058083
rs354439
rs1454361
rs722290
rs873196
rs4530059
rs1821380
rs8037429
rs1528460
rs729172
rs2342747
rs430046
rs1382387
rs9905977
rs740910
rs938283
rs8078417
rs1493232
rs9951171
rs1736442
rs1024116
rs719366
rs576261
rs1031825
rs445251
rs1005533
rs1523537
rs722098
rs2830795
rs2831700
rs914165
rs221956
rs733164
rs987640
rs2040411
rs1028528

Sr.No
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

STR name
D1S1656
TPOX
D2S441
D2S1338
D3S1358
D4S2408
FGA
D5S818
CSF1PO
D6S1043
D7S820
D8S1179
D9S1122
D10S1248
TH01
vWA
D12S391
D13S317
PentaE
D16S539
D17S1301
D18S51
D19S433
D20S482
D21S11
PentaD
D22S1045
DXS10135
DXS8378
AMELX
DXS7132
DXS10074
DXS10103
HPRTB
DXS7423
DYS505
DYS570
DYS576
DYS522
DYS481
DYS19
DYS391
DYS635
DYS437
DYS439
DYS389I
DYS389II

Sr.No
48
49
50
51
52
53
54
55
56
57
58
59

STR name
DYS438
DYS612
DYS390
DYS643
DYS533
Y- GATA- H4
DYS385a-b
DYS460
DYS549
DYS392
DYS448
DYF387S1
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and incubating for 3-5 mins at room temperature. The slides were washed with PBS to remove
the beads and terminate DNA digestion. The nuclei were lysed by incubation overnight at 65C
with 0.5 µL/cell of Arcturus PicoPure DNA lysis buffer (Applied Biosystems), and then
inactivated at 95C for 30 min.
Placental villi (20-25 mg) were dissected and suspended in 100 µL PBS. Ten µl of
immobilized DNase was added and shaken for 10 min at room temperature to ensure efficient
extracellular maternal and fetal DNA digestion. DNase beads were removed by washing in PBS.
DNA was extracted from the tissue, using the Qiagen DNeasy Blood & Tissue Kit.
All DNA was purified using the Qiagen MinElute PCR purification kit, eluted in a final
volume of 20 µL, and quantified using the PicoGreen assay.
Library preparation for ForenSeq
DNA libraries were prepared with the ForenSeq DNA Signature Prep Kit (Illumina),
using primer mix A, as instructed by the manufacturer. Individual samples were quantified by
Qubit, and analyzed using Agilent high-sensitivity DNA chips prior to library normalization.
The percentage of libraries between 200-1000 bp was calculated based on the library traces, and
was mixed accordingly at the genomic core facility at the University of Illinois. A pool size of
200bp-1 kb was selected, and the size-selected negative controls were mixed into the pool. The
samples were sequenced on a MiSeq FGX system including positive and negative controls
(Illumina).
ForenSeq data analysis
ForenSeq with primer mix A analyzes 94 SNP loci and 59 STR loci on all human
chromosomes (Figure 17c, Table 6). The ForenSeq Universal Analysis software provides a run
quality report and detailed genotype. From this report, data was extracted and allele percentages
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determined, using the read depth of each STR or SNP. For STR data, the two dominant alleles
with highest relative peaks were used for further analysis.
To determine the purity of fetal DNA, the level of contamination with maternal DNA was
calculated from the SNP data. For each sample triad (fetal, maternal, placental), the homo- or
heterozygosity of each SNP was determined, first in the placenta, then comparing to fetal, and
the percentage deviation of the fetal DNA was calculated.

Deviations from homo- or

heterozygosity were also calculated in the SNP profile of maternal DNA to determine a threshold
of technical and/or biological variation.

Maternal and placental SNP profiles were then

compared, and the non-informative SNPs (i.e., identical maternal and placental alleles) were
filtered out. For the informative SNPs, the deviations obtained from the maternal sample were
subtracted from the fetal sample and multiplied by two (to account for two maternal alleles
contributing to the fetal sample), yielding the percentage of maternal contamination.
To investigate whether the fetal genotype could be accurately determined in the absence
of reference DNA, autosomal STR’s were used. The dominant alleles with highest relative peaks
were summed, to establish the median and range, which discriminated the pure (<15%
contamination) from impure samples.

Pure samples had median STR alleles >85%, while

impure samples had median STR alleles <80%. To establish a cutoff for discriminating pure
from impure samples, 82.5% was chosen. The determined threshold for autosomal STR alleles
then provided 100% correct calls for the fetal haplotype.
For SNP analysis, a threshold of 10% allowed a maximal maternal contamination of
approximately 20%. Therefore, a homozygous SNP was only analyzed in fetal samples when the
variant allele represented either 0-10% or 90-100% of the read depth, while heterozygous SNPs
were only analyzed when the variant allele read depth was between 40 and 60%.
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Results
Isolation and characterization of fetal cells
Using TRIC (Bolnick et al., 2014), maternal and fetal cells were isolated from
endocervical specimens (n=20), as illustrated in Figure 17a, at gestational ages ranging from 5 to
19 weeks (8.3 ± 3.6 weeks; Table 7). Matched maternal cells, and placental tissues were used as
references for analysis. An average of 282 trophoblast cells (range, 170-410) were separated
from maternal cells that were in excess of 200,000 cells. Purity of fetal cells was assessed by
staining for expression of the trophoblast-specific protein, human chorionic gonadotropin β
subunit (β-hCG). On average, 89.2% (± 5.0%) of the isolated fetal cells stained positive for βhCG, which was completely absent in maternal cells (Table 7, Figure 17a, lower panel). The
gender of the isolated cells was determined by fluorescence in situ hybridization (FISH) for the
X and Y chromosomes. In pregnancies with a male fetus, the fetal cells showed positive probe
binding for both X and Y chromosomes, as expected, while the maternal cells were positive only
for the X chromosome (Figure 17a, lower panel). Fetal and maternal DNA was obtained from
234 (± 75) and 335 (± 104) cells, respectively, using endocervical specimens (n=20) and small
pieces of placental tissue. (Table 7). For fetal cells, nuclear isolation combined with DNase
treatment after TRIC (Figure 17, Material and Methods) was necessary to ensure high quality
fetal DNA samples (Figure 18).
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Figure 17. Trophoblast isolation, assessment of cell purity, and fetal DNA isolation for sequencing.
a, Endocervical specimen collection and immuno-magnetic separation of trophoblast cells, using antiHLA-G coated magnetic nanoparticles [1-6]. Below, trophoblast purity assessment by
immunofluorescence staining for β-hCG (green), maternal and IgG were negative (first three panels), and
screening for gender by fluorescent in situ hybridization (FISH) for the X and Y chromosomes (right
panel, male sample). b, Top panel illustrates nuclear DNA isolation from the fetal cells [1]. Maternal
DNA is blue, fetal cells and DNA are red [2]. Fetal nuclei remain adherent to slides after limited cell
proteolysis [3]. Nuclei are lysed [4], providing fetal DNA [5]. The lower panels show
immunofluorescence microscopic images of fetal cells during procedure. F-actin in green (FITCphalloidin), and nuclei in blue (DAPI). Pepsin digestion removed F-actin. DNase immobilized on beads
degraded residual maternal DNA. Nuclei were used for fetal DNA purification. c, Top panel illustrates the
steps for targeted sequencing using the Forenseq platform [1-4]. The lower panel shows the locations of
the 59 STR (blue) and 94 SNP (red) sites targeted across the human genome. Size bars, 100 μm
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Table 7. Overview of samples and results for targeted sequencing approach
Sample
ID

Gestational
Age

Tropho‐
blast cell
purity
(% β‐hCG)

SA
SB
SC
SD
SE
SF
SG
SH
SI
SJ

5 wks
5 wks
5 wks
6 wks
6 wks
6 wks
6 wks
6 wks
6 wks
7 wks

86
89
91
85
92
93
89
86
89
92

SK

8 wks

SL
SM
SN
SO
SP
SQ
SR
SS
ST

8 wks
8 wks
8.4 wks
9 wks
9 wks
11 wks
13 wks
14wks
19 wks

Autosomal STR alleles
in TRIC
Fetal
Gender

# of Informative SNP’s
% Fetal
Fraction (%
maternal
fraction)

In sample
triads (%)

In Fetal cells
after
threshold (#
total SNP’s
detected)

Incorrectly
called in
Fetal cells

Media
n

Range

Male
Female
Female
Female
Male
Male
Male
Female
Male
Female

94.8
85.5
89.1
91.9
86.4
88.1
93.3
92.7
95
89

85.6 - 100
75.1 – 100
73.5 – 100
80.8 – 98.7
85.7 – 96.9
73.2 - 99.4
84.9 – 100
77.8 - 98.5
88.9 – 100
77.7 – 96.6

97.6 (2.4)
92.2 (7.8)
87.2 (12.8)
95.2 (4.8)
85.6 (14.4)
75.6 (24.4)
93.9 (6.1)
98.6 (1.4)
100 (0.0)
82.1 (17.9)

41 (43.6)
44 (44.7)
51 (54.3)
42 (44.7)
30 (40.4)
49 (52.1)
48 (51.1)
51 (54.3)
38 (40.4)
41 (43.6)

41 (93)
31 (77)
39 (82)
40 (89)
25 (62)
11 (55)
45 (91)
47 (89)
35 (90)
19 (68)

0
0
0
0
0
0
0
0
0
0
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Female

89

72.3 - 100

82.4 (17.6)

42 (44.7)

22 (74)

0

96
96
92
85
94
85
91
90
80

Female
Female
Female
Male
Male
Female
Male
Male
Female
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90.2
93.3
93.6
91.9
91.9
87.4
91.7
93.2

79.6 - 99.4
78.3 - 100
76.5 – 99.2
79.8 - 100
81.9 – 100
73.8 - 97.6
77.7 - 100
81.8 - 100
85.3 – 99.5

97.2 (2.8)
90.8 (9.2)
92.8 (7.2)
92.9 (7.1)
100 (0.0)
95.9 (4.1)
91.9 (8.1)
92.6 (7.4)
98.7 (1.3)

40 (42.6)
47 (50)
45 (47.9)
52 (55.3)
38 (40.4)
41 (43.6)
57 (60.6)
44 (46.8)
48 (51.5)

38 (87)
44 (91)
42 (90)
46 (90)
37 (92)
39 (89)
41 (77)
44 (93)
48 (92)

0
0
0
0
0
0
0
0
0

Figure 18. Comparison of
fetal fractions obtained
with/without
nuclear
isolation. The stack bar graph
for the distribution of copurifying maternal DNA
(calculated as percentages and
represented
in
gradient
shades) in TRIC cells among
informative SNPs. Samples
S1-3, sequenced without fetal
cell nuclear isolation show
high proportion of maternal
SNP’s. Samples S4-6 were
subjected to nuclear isolation
before sequencing and show
decreased
detection
of
maternal SNP’s.
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Targeted multiplex next generation sequencing
We determined whether fetal DNA obtained by TRIC possessed the fidelity for reliable
detection of single nucleotide mutations, as well as small DNA insertions and deletions. To do
this, we utilized the ForenSeq platform to genotype and distinguish the fetus and mother, using
small quantities of DNA (Churchill et al., 2016; Kidd et al., 2006; Sanchez et al., 2006) to target
59 STRs (27 autosomal, 7 X, and 24 Y haplotype markers) and 94 SNPs on all 22 autosomes
(Figure 17c; Table 6). On average 1.9 ±0.9 ng DNA (n=20) from fetal cells and DNA from
matched placental and maternal cells was sequenced. All 153 loci (Table 6) were sequenced at a
mean sequencing depth of 5268 ± 1714 per STR and 760 ±218 per SNP. The fetal nuclear
isolation strategy developed here generated a high-resolution STR profiles, detailing multiple
shared and discriminatory alleles between mother and fetus.

Detailed analysis revealed

concordance between allelic profiles of fetal DNA obtained by TRIC and reference placental
DNA, which were both distinct from maternal DNA, and provided 100% correct fetal gender
identification in all samples compared to fetal reference DNA (Figure 19a and Table 7).
We observed that all 94 SNP’s were detected in the fetal samples, and matched the
placental reference DNA haplotypes (Figure 19c). Discriminatory SNP analysis, comparing the
maternal haplotype to the reference placental DNA and fetal haplotype (Figure 19 b, d,
Methods), revealed an average fetal DNA fraction of 92.2 ± 6.5%, indicative of low levels of
maternal DNA in the fetal samples (Table 7).

Additionally, all of the maternal and fetal

haplotype pairs lacked forbidden combinations (AA/BB) at any allele (Figure 19b), consistent
with unique individuals, related as parent and offspring. Forbidden combinations were checked
to ensure that in each of the samples at least one allele was derived from the mother thereby
demonstrating that the fetus is related to the mother.
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Figure 19. Targeted sequencing of fetal cells obtained by TRIC. a. d a, Graphical representation of
STR profiles of DNA triads composed of maternal cells (Maternal), fetal cells (TRIC) and placental tissue
(Placenta) from sample SN (Table 2.0). For each DNA sample, the two dominant alleles with highest
relative peaks for a given STR were determined and compared. The adjacent mini-plots show distribution
of shared STR’s (upper mini-plot) and discriminatory STR’s (middle and lower mini-plots). b-d,
Comparisons of allelic frequencies for the sequenced 94 SNPs in sample SD (Table 2.0); b, fetal and
maternal cells, c, fetal cells and placenta, d, maternal cells and placenta.

Accuracy of Haplotype Determinations
Using a threshold filter derived from reference placental DNA to account for variant
reads due to maternal DNA that co-purified with fetal DNA (Methods), homozygous SNPs were
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only called when the variant allele reads were within 0-10% or 90-100%, while heterozygous
SNPs were only called between 40 and 60% (Methods). We observed that even after the
threshold was applied, we were able to call 89% ± 12% of all the 94 SNP’s in fetal samples
(Table 7). The haplotype of any SNP that passed the filter always matched the placental
reference DNA and was, therefore, correctly determined. The number of SNPs recovered after
filtering correlated with the amount of co-purifying maternal DNA present. Stratifying the
twenty samples, we found that the presence of less than 5% maternal DNA (n=8) resulted in 95.4
± 2.5% recovery of the SNPs available pre-filtering; for 6.1% to 9.2% maternal DNA (n=7),
average recovery was 92.5 ± 7.3% of SNPs; whereas higher contamination (12.8% to 24.4%,
n=5) reduced recovery of SNPs to 62.5 ± 15%.
The data were further analyzed to determine when the purity of the fetal fraction was
sufficient to call the correct fetal haplotypes in the absence of reference (e.g., placental) DNA.
An internal quality control was established using the median summed autosomal STR allele
percentage (Methods). A median summed autosomal STR allele percentage greater than 82.5%
(achieved in 15 of the 20 samples) was required to consider a sample adequately pure for precise
single nucleotide resolution. In general, any given SNP in any samples that passed the filter was
correctly called.
Discussion
Genetic disorders pose a significant risk for the newborn. After forty-five years of
exploring the diagnostic utility of fetal trophoblast cells residing in the female reproductive tract
(Imudia et al., 2010; Shettles, 1971), we report in this study that the entire fetal genome can be
analyzed with a noninvasive and standardized procedure, beginning at three weeks post
conception (five weeks after the previous menses). The TRIC protocol, followed by nuclear
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Figure 20. Approaches to obtain fetal DNA for prenatal testing in ongoing pregnancies in
comparison to trophoblast retrieval and isolation from the cervix (TRIC). Sources of fetal DNA
throughout early pregnancy are illustrated at the maternal-fetal interface. Amniocentesis is available
beginning at 12-15 weeks of gestational age (GA) and is invasive, but provides intact fetal cells from
amniotic fluid for DNA isolation. Chorionic villous sampling (CVS), available at 9-10 weeks of GA,
provides fetal DNA from intact cells of a placental biopsy obtained invasively. Fetal cells are extremely
rare in maternal blood. However, fragments of fetal DNA released from degrading placental cells
accumulate in maternal blood with increasing GA as cell-free fetal DNA. This cell free fetal DNA can be
obtained non-invasively from maternal blood, beginning at 8-10 weeks of GA and can be analyzed using
multiple parallel sequencing combined with extensive computational analysis to distinguish it from cellfree maternal DNA. Hundreds of intact trophoblast cells can be safely retrieved non-invasively in Pap
smears using a cytobrush. TRIC captures trophoblast cells migrating into the reproductive tract that
accumulate in the endocervical canal beginning at 5 weeks of GA without negative effects early GA or
maternal obesity found with cell free DNA. (Table 7)
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isolation, provided access to the full, unfragmented fetal genome for analysis earlier in gestation
than any procedure currently in practice (Figure 20).
Previous studies have suggested genetic testing protocols using fetal cells captured from
the cervix by size selection and laser micro dissection (Bussani et al., 2007; Bussani et al., 2002;
Katz-Jaffe et al., 2005; Mantzaris and Cram, 2015; Pfeifer et al., 2016). A critical obstacle was
the inability to generate pure, well-characterized fetal cell populations. The lack of sufficient
quantities of fetal DNA for reliable molecular analysis limited DNA characterization and
reproducibility. As a result, those approaches have never been adapted for clinical use.
To overcome these limitations, we have developed a rapid isolation protocol that
provides fetal cells and DNA within one day, using immunomagnetic isolation of fetal cells
(Bolnick et al., 2014). Although trophoblast HLA-G expression decreases in women with
placental disorders, such as preeclampsia (Goldman-Wohl et al., 2000), fetal cell yield is not
significantly hindered in those pregnancies (Fritz et al., 2015b), which reduces dropouts due to
lack of DNA. Initial experiments that isolated DNA from fetal cell extracts (Figure 17) failed to
reliably provide a high fetal DNA fraction that was adequate for clinical analysis, suggesting copurification of maternal DNA fragments bound to the fetal cells. This complication has likely
hindered comprehensive analysis of the fetal genome by other groups working with specimens
collected from the reproductive tract. Nuclear isolation eliminated the maternal DNA, resulting
in unprecedented fetal DNA purity from transcervical specimens. An average fetal fraction of
91.5% was obtained before 10 weeks of gestation, with a fetal fraction up to 99.9% as early as 6
weeks of gestation.
Next generation sequencing is a powerful tool for both global analysis of the genome and
targeted sequencing of selected loci. Whole genome and exome sequencing have the advantage
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of identifying chromosome structural anomalies, as well as de novo mutations. However, those
approaches require larger quantities of DNA for complete coverage and adequate read depth
(>30x) in order to obtain single nucleotide resolution. The small fraction of fetal DNA available
in cell-free DNA limits its usefulness to chromosome copy number variance testing as a
noninvasive perinatal screen. However, approximately 90% of congenital defects are not caused
by aneuploidies (Christianson and Modell, 2004). By accessing intact fetal cells with entire
genomes, the TRIC protocol reliably provides comprehensive fetal genetic analysis as
demonstrated here using targeted sequencing.
Targeted sequencing without whole genome amplification is currently the method of
choice for diagnostic screening of specific genomic regions and gene mutations. It requires less
DNA, provides greater depth (>300x), and is therefore a reliable, low cost approach.
Additionally, data is easier to analyze compared to whole genome sequencing due to the limited
number of loci involved. It avoids as well the potential of uncovering maternal disorders,
including cancers that can be detected with the current NGS shotgun sequencing approaches
(Bianchi et al., 2015).
With as few as 125 cells, the exact fetal genotype was determined reliably by targeted
multiplex sequencing of 157 loci across all chromosomes. However, the limit at which cycle
saturation would cause a bias is not currently known. SNPs are naturally occurring single
nucleotide variations in the genome that, from a technical standpoint, are comparable to
pathogenic point mutations. Similarly, STRs mimic small insertions and deletions in the genome
that distinguish some clinically-relevant mutations. Targeted sequencing of SNPs has been
extended on a large scale for aneuploidy analysis of cell free fetal DNA (Wong and Lo, 2016).
The ability to detect both SNPs and STRs is evidence that prenatal genotyping by TRIC is
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capable of detecting any genetically-transmitted disease.
Achievement a high fetal fraction through TRIC and nuclear isolation solves a critical
problem in the detection of gene mutations in the first trimester of pregnancy. Here, we provide
proof that recessive, autosomal, single nucleotide polymorphisms in a male fetus can be easily
detected without the need of paternal haplotyping, based on our analysis. The approach used in
this study can be effortlessly adjusted to test for any genetic variation or disorder.

If

discriminatory SNPs or STRs are included in the targeted sequencing strategy, contaminating
maternal DNA can be quantified and subtracted to determine the fetal haplotype. Therefore,
genotyping is straightforward and can be adjusted to established commercial pipelines. With
advances in targeted multiplex sequencing approaches, Nicolaides et al. have successfully used
19,488 parallel reactions to detect aneuploidies in cell free DNA (Nicolaides et al., 2013), which
should be feasible using fetal cells from the cervix to screen aneuploidies, as well as multiple
genetic disorders.
TRIC can potentially fill an important gap in current noninvasive prenatal testing with the
precision of current invasive technology, but unhampered by limitations due to a large maternal
DNA fraction, rapid fetal DNA catabolism, early gestational age or maternal obesity. Due to its
simplicity, TRIC will in the future enable prenatal genetic analysis in a diagnostic clinical setting
without the necessity of complex bioinformatics for interpretation of massively parallel
sequencing. Isolation of fetal cells by TRIC holds not only promise for prenatal genetic testing,
but also provides a novel approach to investigate trophoblast cells in ongoing pregnancies
(Imudia et al., 2010), exploring their biology and relationship to the various placental
insufficiency syndromes that jeopardize fetal and maternal health.
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CHAPTER 5 - TRANSCRIPTOMIC PROFILING FOR CHARACTERIZATION OF
CELLS ISOLATED BY TRIC
Abstract
The survival and differentiation of extravillous trophoblast (EVT) cells at the beginning
of pregnancy is crucial, and deficiencies are linked to diseases of uteroplacental insufficiency,
including early pregnancy loss, fetal growth restriction and preeclampsia. It is anticipated that
EVT gene expression in the first trimester is altered prior to the onset of overt disease in the third
trimester.

Fetal cells that express EVT lineage proteins can be obtained from ongoing

pregnancies by Trophoblast Retrieval and Isolation from the Cervix (TRIC), and provide a novel
platform for examining gene expression.

Transcriptomic analysis using next-generation

sequencing (NGS) offers as an unbiased approach to identify differentially expressed transcripts
in these fetal cells during the first trimester from normal and pathologic pregnancies. RNA
isolated from the fetal cells was quantified and assessed for quality to establish its stability
during TRIC. NGS identified 409 genes differentially expressed between the fetal cells and
maternal cells from the same cervical specimens. However, no significant differences in gene
expression were noted between replicate RNA aliquots, or between fetal cells from different
patients.

Bioinformatics, including gene ontology pathway analysis and BioPython library

demonstrated that 21 genes were EVT specific. This study suggests that not only can RNA of
adequate quality be isolated from cells obtained by TRIC, but it can be used to reliably
interrogate the transcriptome. TRIC and NGS could provide for the first time molecular profiles
that reveal early pathophysiological events postulated to occur in EVT cells at the inception of
pregnancies that develop uteroplacental insufficiencies and cause major obstetric disorders.
Introduction
The placenta is a multifunctional organ that not only provides a fetal-maternal interface,
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but is also the site of exchange of nutrients, oxygen, metabolites and other molecules between
the mother and the fetus (Dilworth and Sibley, 2013). The placenta is important for the survival
of the fetus, as well as health of the mother. They are composite organs consisting of a
trophoblast compartment that enables nutrient and gas exchange between the fetal and maternal
blood circulations, and mesodermal lineages that form the umbilical cord and the fetal portion of
the placental vasculature (Chaddha et al., 2004). The trophoblast compartment consists of a
population of villous cytotrophoblast cells that fuse into syncytiotrophoblast or proliferate along
the fetal-maternal interface to form cell columns and undergo a well-defined differentiation into
invasive extravillous trophoblast (EVT) cells. The synctiotrophoblast layer is responsible for all
nutrient and gas exchange between the maternal and fetal blood circulations (Knofler and
Pollheimer, 2013). EVT cells discharge through the maternal mucosal fluids after invading the
uterine wall, where they are deployed to facilitate spiral artery remodeling and immune
modulation at the fetal-maternal interface.
Trophoblast Retrieval and Isolation from the Cervix (TRIC) is a novel experimental
platform (Bolnick et al., 2014) that provides a novel approach to non-invasively acquire fetal
cells hypothesized to be EVT that are central for proper placentation. TRIC uses the EVT
lineage protein, HLA-G, to efficiently separate maternal cells from fetal cells in endocervical
specimens. The isolated cells are positive for β-hCG (>98%), while the depleted maternal cells
do not express this trophoblast product (Bolnick et al., 2014; Fritz et al., 2015a). Cells
isolated by TRIC are clearly fetal in origin, based on the presence of a Y chromosome when the
fetus is male (Bolnick et al., 2014), and comparison of haplotypes between maternal and fetal
cells isolated during TRIC (Chapter 4). Two other trophoblast marker proteins, cytokeratin 7
(KRT7) and placental lactogen (CSH1) are uniformly expressed in the isolated fetal cell fraction
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(Bolnick et al., 2014). The phenotype of the isolated fetal cells was investigated using ICC,
demonstrating that they express several EVT markers (ITGA1, CDH5, PECAM1, MMP9, HLAG), but lack villous trophoblast markers (ITGA6, CH1, PSG1) (Bolnick et al., 2014).
Uteroplacental insufficiency, defined as inadequate perfusion of the placenta, is a
pathology associated with several perinatal disorders, including early pregnancy loss (EPL),
intrauterine growth restriction (IUGR) and preeclampsia (PE) (Hossain and Paidas, 2007;
Papageorghiou et al., 2004). There is compelling evidence that uteroplacental insufficiency
originates with the failure of EVT cells to properly differentiate, invade intravascularly, and
convert the uterine spiral arteries to low resistance, high volume conduits of maternal blood into
the intervillous space (Chaddha et al., 2004). These events transpire during the first trimester,
well before clinical symptoms of IUGR or PE occur. However, direct evidence that the EVT
cells are altered in the first trimester prior to development of those disorders is lacking. Fritz et
al examined a set of proteins associated with uteroplacental insufficiency in fetal cells obtained
by TRIC between 5 and 10 weeks of gestational age (GA) and found significant differences in
six of the seven proteins between control pregnancies and those ending in EPL (Fritz et al.,
2015a), suggesting that the molecular profiles of the EVT-like fetal cells reflect pregnancy
status.
It is hypothesized that fetal cells obtained from the cervix by TRIC have a similar
phenotype and physiology to EVT cells residing in the basal plate and placental bed.
Understanding the relationship between EVT cells in the placenta and cervix will establish the
developmental significance of the cells, and their utility as an experimental paradigm to
investigate placental pathophysiology. As an initial assessment, the transcriptome of fetal cells
obtained by TRIC will be compared to that of the maternal epithelial cells from the cervix to
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establish their unique RNA profile and to determine if the differentially expressed genes are
indicative of an EVT phenotype. Because EVT invasion and conversion of the maternal spiral
arteries occurs in the first and early second trimesters, it is hypothesized that comparison of fetal
cells obtained by TRIC from pregnancies that develop severe placental insufficiency causing
EPL with fetal cells isolated from pregnancies with healthy term deliveries will generate a
unique set of differentially expressed genes associated with deficient trophoblast development,
and could help identify novel disease biomarkers with very high sensitivity and specificity for
future preclinical testing. These studies will provide a clearer view of the utility of fetal cells
obtained by TRIC from ongoing pregnancies for investigating early placentation and
pathological etiologies, and the potential of TRIC as a platform for perinatal interrogation of the
placenta to predict maternal risk of placenta-based disease.
Materials and Methods
Sample Collection
Pregnant patients (N=50) were recruited at 5-20 weeks GA with informed consent and
approval of the institutional review board of Wayne State University. EVT cells were obtained
with a ThinPrep kit (Hossain and Paidas, 2007) and immediately fixed during the PAP smear
procedure, preserving proteins and nucleic acids, including RNA. Prior to fetal cell isolation, all
cells were pelleted to remove ThinPrep fixative and then cross-linked with 10 ml of 2%
paraformaldehyde for 10 min. This was followed by washing the cells 3 times with 10 ml of
PBS by centrifugation and resuspension. Fetal cells were then purified by immunomagnetic
isolation with anti-HLA-G, according to the TRIC protocol (Bolnick et al., 2014). Recovery after
immunomagnetic isolation averages 746 ± 59 (Bolnick et al., 2014)
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RNA Extraction
Fetal RNA was isolated after de-crosslinking, using a Qiagen FFPE RNA kit, incubating
at 56ºC for 15 min and 80ºC for 15 min and incubating with 1500 Kunitz DNase for 15 min prior
to RNA extraction. Isolated RNA was quantified with the RNA Pico Kit (Agilent Technologies),
and its purity assessed using an Agilent 2100 Electrophoresis Microfluidics Analyzer. The
amount of RNA per cell recovered is reported in Figure 21C (Results).
Library Preparation
Eleven patients were selected for RNAseq after outcomes were determined from patient
medical records. A control cohort of pregnancies with uncomplicated term deliveries (n=9) and
adverse pregnancy cohort (n=2) were identified and selected for library preparation. RNA
libraries were prepared from both fetal and maternal cells isolated by TRIC using the ScriptSeq
v2 RNA-Seq Library Preparation Kit (Epicenter) and 500 pg of fragmented RNA. Uniquely
barcoded adaptors were ligated to the RNA, followed by PCR amplification and library
purification. Each uniquely barcoded sample was quantified and its quality assessed, using the
High Sensitivity DNA Chip (Agilent Technologies). The cDNA was combined from barcoded
individual libraries before multiplex sequencing, eliminating any sequencing lane effects.
Paired-end sequencing was performed for 50 cycles using the Illumina HiSeq-2500 sequencer.
Data Alignment & Mapping
RNA sequencing data was first processed with demultiplexing software (Casava 1.8.2,
Illumina). It was then aligned to the human genome build CRCh37.p7/hg19, using TopHat2 ver
2.0.13 (Kim et al., 2013), and to the ribosomal sequences 18S and 28S, using the bioinformatics
tool Novoalign (Novocraft, 2010). Novoalign determined unique alignments that were used to
generate 1000 reads per coding segment per sample. The reads thus generated were converted
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into bed.files and imported to the Genomatix Genome Analyzer (GGA) (Genomatix Software
GmbH). The GGA, using RNA-seq analysis, generated data in the form of Reads Per Kilobase
of exon per Million fragments mapped (RPKM) for 25,000 genes in the database. A set of
differentially expressed genes (DEGs) were identified with bioconductoR package DESeq2
(Anders and Huber, 2010). A gene was considered significantly altered if the adjusted p-value
was < 0.05. p-values were calculated by the DeSeq2 program. DEGs were subjected to Ingenuity
Pathway Analysis (IPA) to identify the top functional interaction networks and key central
regulatory genes. The most significant network in which the differentially expressed genes were
enriched was selected and illustrated.
qPCR
The quality of the fragmented RNA was validated by semi-quantitative qPCR for
HBEGF, MMP2 and 18sRNA, using SYBR green and a CFX384 BioRad thermal cycler (Life
Technologies). NGS data was validated using qPCR with primers (IDT) for genes listed in Table
8. RNA for each of the samples used in NGS was converted to cDNA, using 4 µl iSCRIPT
(BioRad) and pre-amplified for x cycles in a multiplexed reaction using all primers and
SsoAdvanced PreAmp Supermix (BioRad). Samples were then target-amplified with individual
primers. After each of the samples was target-amplified, qPCR was quantified by delta (Bustin et
al., 2009) analysis.
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Table 8: Genes used for qPCR validation
Gene name
HLA-G
KRT7
CDH5
MMP9
ITGA6
CDH1
CD38
CSF1
DDX39A
RBM15
TLR1
AMBP
FGF23
KCNQ5
NUNDT9
TRPC7
C3
CCND1
FGF2
HSP90B1
PRDX6
SUMO2
DUSP1
FOS
IL1B
IL8
JUNB
NFKBIA
SOC3

Forward Primer
GTG TGG TAC TTT GTC
TTG AGG A
GGT CAG CTT GAG
GCA CTG
AAG AAC TGG CCC
TTG TGA C
CGT CGA AAT GGG
CGT CT
TTG GAC TCA GGG
AAA GCT ATT G
CTG AGG ATG GTG
TAA GCG ATG
TCC GAA GAT GTG
GAC TTG C
TCT TTC AAC TGT TCC
TGG TCT AC
CAC CGA AGA ACA
CAG ACA CC
TCT TCT TGT TCT CAT
ACC TAA CTC C
AGA CAT TCC TAA
AGG TAG AAG CTG
GTA TCT GTT TTC TCA
TAA GCT CCA G
TAT CTT CTG CTC ATC
ACA CCT G
CTT CCT TGC CAT CCT
CTA TAT CG
TTC TGT AAG GAG
TTG GA GCT TC
CAT CAA AGT AAG
ACA GCC AGA GT
TGT TAA ATG GCT
GAT CCT GGA G
GTT CCA CTT GAG CTT
GTT CAC
GCC AGG AAC AGC
TAC CAC
AAG GAC TAC TGC
ACC AGA ATG
TGT GAC AGC TCG
TGT GGT GT
CCT GCA CAG TTG
GAA ATG GAG G
ACC ATC TTC CAT GCT
TAC CAC
ACA CTC CAA GCG
GAG ACA GA
TGG CCT TGG GCC
TCA AGG A
TGT CTG GAC CCC
AAG GAA
CGG ATG TGC ACT
AAA ATG GAA C
CAG GAG ACG TGA
AGA TGC TG
CAA GGA CGG AGA
CTT CGA TTC

Reverse Primer
AGA GTA GCA GGA
AGA GGG TT
ACC ACA AAC TCA
TTC TCA GCA
CAG CCT TTC TAC CAC
TTC CAG
ACA TCG TCA TCC
AGT TTG GTG
GAT CTC CAC TGA
GGC AGT TAT G
GTC TGT CAT GGA
AGG TGC TC
TCT CCA TCC TCT CTT
CAC CA
TGT CGG AGT ACT
GTA GCC A
TCA ACG GAC AGG
TGA CG
AGT TCT CCC AGC
AGT TCC T
GAA GAA ATC AGG
ATA ACA AAG GCA
GAC AGG ATG ACA
GTG AGC AC
GCC AGG AAC AGC
TAC CAC
AGT GTT TTC TAC CAT
CCC TGA G
AAG GAA AGA CTG
TGG AGA ATG G
TGC TCA ACA TGC
TAA TAG CCA
GCC ATG TCT TTC TCG
TTG TTG
GCT GTG CAT CTA
CAC CGA
TAT CTT CTG CTC ATC
ACA CCT G
TGT TTC CGA AGA
CGT TCC AC
GTC AGC TGG AGA
GAG ATG AC
AGT AGA CAC CTC
CCG TCG TCT GCT
AAC TTG GCA CTG
CAT TTT GG
CTG AGC TGC CAG
GAT GAA CT
CTA CAC TCT CCA GCT
GTA GAG
CAT CTT CAC TGA TTC
TTG GAT ACC
GGT TTC AGG AGT
TTG TAG TCG T
AGT TGA GAA TGA
AGG TGG ATG A
GGA AAC TTG CTG
TGG GTG A

Trophoblast marker
Trophoblast marker
Invasion/migration marker
Invasion/migration marker
Epithelial marker
Epithelial marker
Trophoblast
specific
genes
upregulated in fetal cells when
compared to maternal cells.

Trophoblast
specific
genes
downregulated in fetal cells when
compared to maternal cells.

Genes upregulated in fetal EPL
cells when compared to fetal
normal

Genes downregulated in fetal
EPL cells when compared to fetal
normal
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Results
TRIC provides stable RNA from isolated cells
To assess RNA stability during TRIC, the HTR-8/SVneo cell line was treated similarly to
cervical specimens collected in the ThinPrep fixative.

Both fresh cells and cells fixed in

ThinPrep produced intact RNA, however, after a series of PBS washes or incubations to mimic
the TRIC protocol at both 4C and room temperature degradation of RNA was apparent (Figure
21A), possibly due to introduction of endogenous RNases.
Formaldehyde covalently binds proteins and nucleic acids by reacting with primary
amino groups, and prevents loss of highly soluble nucleic acids by inactivating endogenous
RNases. Aldehyde crosslinkers are reversible by heat and salt treatment (Niranjanakumari et al.,
2002). TRIC was modified to incorporate formaldehyde crosslinking prior to removal of cells
from the ThinPrep fixative to preserve RNA integrity. Fetal and maternal RNA was extracted
after de-crosslinking, which resulted in fragmented RNA (Figure 21B). RNA extracted from
ThinPrep-fixed cells prior to TRIC (crude) and maternal or fetal cells separated by TRIC using
the crosslinking and de-crosslinking protocols produced equal amount of RNA/cell (Figure 21C).
This finding suggests that the formaldehyde cross-linking prevents RNA degradation. qPCR for
several known mRNAs in the isolated maternal and fetal cells produced Ct values comparable to
RNA isolated from the crude cells (Figure 21D), suggesting that fragmentation following decrosslinking does not impact the over-all quality of the RNA extracted after TRIC for use in
mRNA quantification. The fragmented RNA is ideal for downstream NGS (Head et al., 2014).
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Figure 21. Assessment of RNA quality and integrity. A and B. Gel Images (Agilent 2100 Bioanalyzer)
of total RNA. A. RNA extracted from HTR-S/Vneo cells was immediately examined (Fresh), or fixed
with ThinPrep (Fixed), washed in PBS (Fixed + Wash) and processed by the TRIC protocol (Separation)
at either 4C (Cold) or room temperature (RT). High-quality samples (Fresh and Fixed) produced two
distinct bands corresponding to the 18S and 28S ribosomal RNAs. Smearing in the other lanes was
indicative of RNA degradation. B. RNA extracted from fetal (F) and maternal (M) cells isolated using the
formaldehyde crosslinking protocol showed smearing and strong bands at ~200 bp, indicative of
fragmentation. C. RNA recoveries, quantified by Agilent Bioanalyzer, were determined from crude cells
in ThinPrep fixative and maternal and fetal cells separated by TRIC using the formaldehyde crosslinking
protocol (N = 48 cervical specimens. D. cDNA made from equal amounts of RNA in C was assayed by
qPCR with primers for the indicated RNAs

Transcriptomic analysis of cells isolated by TRIC from normal term pregnancies
Total RNA was prepared after TRIC, using the formaldehyde crosslinking and
decrosslinking protocol from cervical samples obtained from patients with normal full term
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deliveries (n=9, Table 9).

The transcriptome was analyzed by RNA sequencing and

bioinformatics to identify genes differentially expressed between the isolated fetal and maternal
cells. A total of 428 differentially expressed transcripts were obtained. Analysis of transcripts
by DESEQ2 for 2.0-fold up or down regulation, generated 209 up and 219 downregulated
transcripts (Figure 22A). Each of the differentially regulated transcripts appeared in MA (Figure
22A) and volcano (Figure 22B) plots, demonstrating at least a 2-fold change and a p-value of
<0.05, respectively as determined by the DESeq2 program.
Table 9. Patient and specimen characteristics
Control

EPL1

EPL2

9 (81)

1 (9.5)

1 (9.5)

26 (22-28)

26

29

0 (0)

0 (0)

1 (100)

9 (100)

1 (100)

0 (0)

Asian, n (%)

0 (0)

0 (0)

0 (0)

Hispanic, n (%)
Unknown, n (%)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

8 (7.6-11.6)

5

7.5

2 (1 - 2)

3

1

Nulliparous, n (%)

7 (78)

0 (0)

0 (0)

Parous, n (%)

1 (11)

0 (0)

0 (0)

Unknown, n (%)

1 (11)

1

1

Normal Spontaneous Vaginal Delivery (NSVD), n (%)

7 (78)

0 (0)

0 (0)

Cesarean section (CS), n (%)

2 (22)

0 (0)

0 (0)

Unknown, n (%)

0 (0)

1 (100)

1 (100)

100 (98-100)

90%

97%

Characteristics
Number, n (% of total)
Maternal age in years, median (IQR)
Ethnicity
Caucasian, n (%)
African, n (%)

Gestational age at the time of sampling in weeks, median (IQR)
Gravidity, median (IQR)
Parity

Delivery mode

Recovered fetal cells
Purity (percentage of β-hCG positive cells), median (IQR)
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Figure 22. Two visualizations of the comparative transcript expression profiles between fetal and
maternal cells A) A) Scatterplot (MA plot) of the log2-fold change in genes expressed in fetal cells
compared to maternal cells generated by DESeq2 on the y-axis, versus baseMean of normalized counts on
the x-axis. The differentially expressed genes (DEGs) (p-values <0.05) were indicated by bold red dots.
The black dots reflect genes with no significant change. B) Volcano plot of RNA-seq data represented by
log2-fold change (x-axis), versus −log10 p-value. The light colored dots represent DEGs (p-value <0.05)
in fetal compared to maternal cells. Among DEGs, 5 up-regulated (red) and 5 down-regulated (blue) genes
were selected for further validation by PCR (see Fig. 23B and C).
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Characterization of cells isolated by TRIC
To characterize the two isolated cell populations (fetal, maternal) the expressions of 8
genes known as markers for trophoblast, epithelial, and invasion/migration were selected and
were examined by real-time qPCR in RNA from all 9 samples. Comparison between cervical
fetal and maternal cells showed expression of trophoblast markers in high abundance in the fetal
cells (Figure 23A). HLA-G and KRT7 were highly expressed compared to the maternal cells.
HLA-G was most highly expressed in fetal cells, which were isolated using anti-HLA-G
immune-separation. CDH5 and MMP9, which are invasion/migration markers were expressed
more in fetal cells than maternal cells. E-Cadherin (CDH1) and integrin alpha 6 (ITGA6), both
epithelial markers, were found in maternal cells, but were very low in the fetal cells, as expected
of the most penetrating EVT (Zhou et al., 1997). Of the differentially regulated genes, ten were
selected based on their association with trophoblast based on a literature search, using BioPython
(Cock et al., 2009). Indeed, transcripts that were upregulated in the fetal cells based on NGS
showed significantly higher mRNA expression by qPCR in fetal RNA compared to maternal
RNA (Figure 23B). Similarly, transcripts that were downregulated in the fetal cells according to
RNAseq showed lower mRNA expression in fetal RNA than maternal RNA (Figure 23C),
validating the NGS data and further confirming that the fetal cells are in fact of trophoblastic
origin.
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Figure 23. Validation of RNAseq by qPCR. A. To characterize the isolated fetal and maternal cell
populations), the expression of 6 genes known as markers for trophoblast, epithelial, and
invasion/migration were selected and examined by qPCR for the 9 control pregnancies. The
expression values are presented as whisker-box plots. Transcript levels of 5 up-regulated (B) and 5
down-regulated (C) genes in the fetal transcriptome identified by RNA-Seq were also validated by
real-time qPCR. * p<0.05; The boxes represent the 25th to 75th percentiles, and horizontal red lines
within the boxes indicate the medians. The whiskers are drawn to indicate 1.5 × Inter Quartile Range
(3rd quartile – 1st quartile).

Gene Ontology Consortium, analysis for fetal and maternal DEGs in normal pregnancies
For gene ontology (GO) analysis, the differentially expressed transcripts (p<0.05)
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between the fetal and maternal cells were analyzed using Ingenuity pathway analysis (IPA). For
this analysis, biological processes were analyzed.

IPA generated the top protein-protein

interaction network with a score of 32 comprising of 27 differentially expressed genes that were
involved in invasion and migration differentiation and proliferation (Figure 24). The prominence
of these pathways suggests that the fetal cells isolated by TRIC have an EVT phenotype.

Figure 24. Protein-protein interaction network. Among the potential regulatory networks identified by
Ingenuity pathway analysis for the genes differentially expressed between fetal and maternal cells
(p<0.05), the top protein-protein interaction network is shown. It contains the key regulatory genes
involved in invasion and migration, differentiation and proliferation. Green symbols indicate genes
downregulated, and red symbols indicate genes upregulated in the in our study.

Transcriptomic analysis and validation of cells isolated by TRIC in Early pregnancy loss
After the pregnancy outcomes were known, 2 cases of early pregnancy loss (EPL) were
identified and compared by NGS to 2 selected control pregnancies (EPL, 5 and 7.5 weeks, Table
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9). Libraries were prepared for both the fetal and maternal cell populations from the EPL
samples and sequenced. Analysis of the sequencing data identified 348 genes differentially
expressed between the fetal cells from control and EPL pregnancies.

Out of the 348

differentially expressed genes, 69 were upregulated and 279 were downregulated, each with a pvalue <0.05 (Figure 25, Tables 10 & 11). Of the differentially expressed transcripts, both up and
downregulated genes were randomly selected for validation by qPCR. Transcripts that were
upregulated in RNAseq data had a higher mRNA expression level in the qPCR analysis (Figure
26A), and those that were downregulated had a higher expression in the normal group (Figure
26B).

However, because there were only two EPL samples, statistical analysis should be

interpreted cautiously. Nevertheless, both the NGS and qPCR data show a similar pattern.

Figure 25. Volcano plot presentation of transcripts in EPL versus control fetal cells. The light dots
represent significantly up- and down-regulated genes at two significant levels (p<0.05 and p<0.01)
shown in the legend to the right. Of all differentially expressed genes, 6 down-regulated (blue dots) and 7
up-regulated (red dots) were chosen for qPCR validation.
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Table 10. Upregulated fetal genes in EPL compared to normal pregnancy
Gene id

log2fold change

Symbol

Gene id

log2fold change

Symbol

2353

3.189

FOS

5209

1.799

PFKFB3

3553

3.147

IL1B

4792

1.79

NFKBIA

8794

2.999

TNFRSF10C

366

1.784

AQP9

6688

2.868

SPI1

54210

1.784

TREM1

3577

2.712

CXCR1

2214

1.771

FCGR3A

2215

2.606

FCGR3B

6648

1.767

SOD2

23135

2.581

KDM6B

5329

1.747

PLAUR

1958

2.504

EGR1

23645

1.737

PPP1R15A

5008

2.502

OSM

3985

1.729

LIMK2

4046

2.489

LSP1

5341

1.702

PLEK

50486

2.455

G0S2

57580

1.685

PREX1

1439

2.401

CSF2RB

2180

1.683

ACSL1

8843

2.392

HCAR3

64744

1.669

SMAP2

4688

2.372

NCF2

7133

1.619

TNFRSF1B

7832

2.314

BTG2

6515

1.597

SLC2A3

55911

2.287

APOBR

3579

1.574

CXCR2

1843

2.276

DUSP1

6402

1.551

SELL

3936

2.26

LCP1

3059

1.484

HCLS1

3576

2.116

IL8

3937

1.477

LCP2

338442

2.092

HCAR2

2495

1.357

FTH1

4332

2.058

MNDA

7439

1.316

BEST1

5552

2.023

SRGN

3851

2.023

KRT4

1230

1.981

CCR1

8291

1.98

DYSF

3133

1.964

HLA-E

3106

1.96

HLA-B

7128

1.955

TNFAIP3

1441

1.932

CSF3R

2212

1.905

FCGR2A

7408

1.868

VASP

7538

1.849

ZFP36

3726

1.848

JUNB

10135

1.845

NAMPT

4542

1.808

MYO1F

9021

1.806

SOCS3

5997

1.806

RGS2

9516

1.803

LITAF
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Table11. Downregulated fetal genes in EPL compared to normal pregnancy
Gene id

log2fold change

Symbol

Gene id

log2fold change

Symbol

6206

-3.665

RPS12

3799

-2.493

KIF5B

595

-3.539

CCND1

3308

-2.484

HSPA4

6181

-3.311

RPLP2

7416

-2.462

VDAC1

7184

-3.284

HSP90B1

1982

-2.461

EIF4G2

10963

-3.186

STIP1

10959

-2.445

TMED2

302

-3.183

ANXA2

6222

-2.436

RPS18

1915

-3.155

EEF1A1

54443

-2.426

ANLN

6124

-3.13

RPL4

5885

-2.422

RAD21

9349

-3.102

RPL23

6152

-2.417

RPL24

6205

-3.102

RPS11

7027

-2.417

TFDP1

3182

-2.992

HNRNPAB

2280

-2.414

FKBP1A

6188

-2.94

RPS3

3939

-2.383

LDHA

7531

-2.886

YWHAE

3326

-2.382

HSP90AB1

811

-2.846

CALR

6176

-2.372

RPLP1

4904

-2.844

YBX1

6232

-2.362

RPS27

5315

-2.84

PKM

1.01E+08

-2.349

RPS10-NUDT3

304

-2.84

ANXA2P2

6160

-2.339

RPL31

6125

-2.788

RPL5

3843

-2.337

IPO5

594839

-2.781

SNORA33

5757

-2.329

PTMA

10594

-2.764

PRPF8

3313

-2.323

HSPA9

7052

-2.723

TGM2

7169

-2.315

TPM2

6135

-2.718

RPL11

22974

-2.31

TPX2

6185

-2.708

RPN2

6194

-2.309

RPS6

821

-2.703

CANX

23193

-2.309

GANAB

1938

-2.691

EEF2

11167

-2.299

FSTL1

654364

-2.647

NME1-NME2

6210

-2.296

RPS15A

6204

-2.63

RPS10

23521

-2.294

RPL13A

3015

-2.617

H2AFZ

3608

-2.294

ILF2

64710

-2.615

NUCKS1

908

-2.285

CCT6A

22948

-2.608

CCT5

2923

-2.279

PDIA3

6128

-2.601

RPL6

93621

-2.278

MRFAP1

6167

-2.599

RPL37

284119

-2.275

PTRF

60674

-2.588

GAS5

6129

-2.269

RPL7

3945

-2.561

LDHB

9761

-2.253

MLEC

6191

-2.547

RPS4X

351

-2.25

APP

2597

-2.546

GAPDH

1937

-2.25

EEF1G

308

-2.54

ANXA5

5901

-2.245

RAN

3688

-2.513

ITGB1

7431

-2.245

VIM

6143

-2.502

RPL19

22836

-2.242

RHOBTB3
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Gene id

log2fold change

Symbol

Gene id

log2fold change

Symbol

8754

-2.226

ADAM9

124801

-1.992

LSM12

629

-2.224

CFB

7913

-1.991

DEK

813

-2.218

CALU

11222

-1.987

MRPL3

2288

-2.21

FKBP4

4288

-1.978

MKI67

619564

-2.206

SNORD72

2195

-1.977

FAT1

5718

-2.191

PSMD12

3069

-1.971

HDLBP

372

-2.19

ARCN1

1.01E+08

-1.971

SENP3-EIF4A1

10112

-2.188

KIF20A

6590

-1.971

SLPI

6155

-2.185

RPL27

84154

-1.967

RPF2

4628

-2.172

MYH10

718

-1.967

C3

29789

-2.165

OLA1

857

-1.967

CAV1

6169

-2.151

RPL38

23435

-1.962

TARDBP

47

-2.151

ACLY

2547

-1.959

XRCC6

5478

-2.147

PPIA

58517

-1.958

RBM25

51406

-2.14

NOL7

1973

-1.958

EIF4A1

6122

-2.136

RPL3

6790

-1.958

AURKA

6130

-2.128

RPL7A

6189

-1.953

RPS3A

125144

-2.126

C17orf76-AS1

2247

-1.947

FGF2

3181

-2.124

HNRNPA2B1

9588

-1.944

PRDX6

2201

-2.123

FBN2

5591

-1.936

PRKDC

4430

-2.122

MYO1B

1282

-1.934

COL4A1

10606

-2.12

PAICS

6134

-1.93

RPL10

10562

-2.117

OLFM4

10568

-1.928

SLC34A2

6233

-2.111

RPS27A

476

-1.924

ATP1A1

6175

-2.106

RPLP0

6133

-1.924

RPL9

8872

-2.104

CDC123

140609

-1.922

NEK7

10197

-2.098

PSME3

6289

-1.921

SAA2

5688

-2.094

PSMA7

7529

-1.92

YWHAB

6217

-2.09

RPS16

805

-1.916

CALM2

488

-2.081

ATP2A2

6171

-1.915

RPL41

6780

-2.067

STAU1

1786

-1.914

DNMT1

1662

-2.065

DDX10

5962

-1.914

RDX

826

-2.054

CAPNS1

7178

-1.911

TPT1

56910

-2.052

STARD7

2131

-1.911

EXT1

7520

-2.013

XRCC5

7812

-1.907

CSDE1

5707

-2.01

PSMD1

23215

-1.907

PRRC2C

3998

-2.007

LMAN1

23028

-1.904

KDM1A

3875

-1.994

KRT18

9805

-1.898

SCRN1

9052

-1.993

GPRC5A

80014

-1.897

WWC2

51400

-1.992

PPME1

6228

-1.895

RPS23
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Gene id

log2fold change

Symbol

Gene id

log2fold change

Symbol

967

-1.893

CD63

689

-1.77

BTF3

3915

-1.89

LAMC1

8886

-1.768

DDX18

3187

-1.886

HNRNPH1

10399

-1.767

GNB2L1

6599

-1.886

SMARCC1

2058

-1.765

EPRS

6613

-1.879

SUMO2

51495

-1.765

PTPLAD1

9221

-1.878

NOLC1

114908

-1.764

TMEM123

51747

-1.874

LUC7L3

10250

-1.762

SRRM1

9897

-1.873

KIAA0196

9793

-1.76

CKAP5

9669

-1.866

EIF5B

23603

-1.756

CORO1C

6136

-1.865

RPL12

8615

-1.751

USO1

6229

-1.865

RPS24

10199

-1.75

MPHOSPH10

1173

-1.862

AP2M1

5411

-1.748

PNN

9055

-1.855

PRC1

6147

-1.746

RPL23A

1984

-1.849

EIF5A

2746

-1.74

GLUD1

4436

-1.847

MSH2

23367

-1.739

LARP1

3184

-1.844

HNRNPD

23524

-1.737

SRRM2

79026

-1.843

AHNAK

4670

-1.736

HNRNPM

6202

-1.839

RPS8

51474

-1.734

LIMA1

11014

-1.838

KDELR2

9987

-1.726

HNRNPDL

54407

-1.837

SLC38A2

10128

-1.723

LRPPRC

26585

-1.835

GREM1

26135

-1.72

SERBP1

7057

-1.832

THBS1

5955

-1.713

RCN2

2935

-1.83

GSPT1

2956

-1.71

MSH6

1315

-1.826

COPB1

27101

-1.709

CACYBP

1E+08

-1.808

MTRNR2L8

6154

-1.707

RPL26

1457

-1.807

CSNK2A1

3192

-1.699

HNRNPU

9045

-1.804

RPL14

445815

-1.696

PALM2-AKAP2

1431

-1.802

CS

214

-1.694

ALCAM

7266

-1.8

DNAJC7

8394

-1.694

PIP5K1A

4673

-1.798

NAP1L1

3376

-1.691

IARS

4057

-1.796

LTF

23020

-1.681

SNRNP200

7414

-1.795

VCL

4144

-1.679

MAT2A

10521

-1.793

DDX17

3178

-1.676

HNRNPA1

94025

-1.791

MUC16

1965

-1.67

EIF2S1

2335

-1.791

FN1

6059

-1.669

ABCE1

10769

-1.779

PLK2

26509

-1.668

MYOF

7082

-1.775

TJP1

1303

-1.668

COL12A1

27316

-1.773

RBMX

1933

-1.668

EEF1B2

11217

-1.771

AKAP2

9804

-1.654

TOMM20

9126

-1.771

SMC3

7430

-1.649

EZR
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Gene id

log2fold change

Symbol

Gene id

log2fold change

Symbol

55706

-1.642

NDC1

22872

-1.574

SEC31A

10276

-1.64

NET1

7874

-1.573

USP7

2040

-1.635

STOM

7415

-1.553

VCP

9879

-1.635

DDX46

1778

-1.53

DYNC1H1

667

-1.634

DST

10490

-1.527

VTI1B

6421

-1.628

SFPQ

9908

-1.522

G3BP2

6385

-1.626

SDC4

8500

-1.512

PPFIA1

6201

-1.624

RPS7

6709

-1.501

SPTAN1

7037

-1.619

TFRC

1981

-1.5

EIF4G1

4076

-1.615

CAPRIN1

1495

-1.488

CTNNA1

4735

-1.591

2-Sep

51280

-1.482

GOLM1

3655

-1.577

ITGA6

79832

-1.477

QSER1

1213

-1.576

CLTC

6651

-1.472

SON

3646

-1.575

EIF3E

Figure 26: Real-time qPCR validation of selected differentially expressed genes. Shown are 6
down-regulated (A) and 7 up-regulated (B) genes in EPL (n=2) compared to control (n=2) pregnancies
for fetal cells. The trends match that predicted by RNAseq results for each of the genes.

Gene Ontology Consortium analysis for DEGs in EPL
For gene ontology (GO) analysis the differentially expressed transcripts between the fetal
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cells from EPL and fetal normal pregnancies were analyzed using Genomatix pathway analysis.
The analysis generated pathways such as apoptosis (Figure 27A), inflammation (Figure 27B) and
placental disease (Figure 27C) that are expected to be involved in placental insufficiency and
EPL. This result supports our hypothesis that cells isolated by TRIC are EVT like fetal cells that
accurately reflect pathologies of pregnancy associated with placental EVT deficiencies. Due to
the small number of subjects (n=2) for the EPL group, Genomatix was used for initial analysis.
Discussion
Uteroplacental insufficiency is at least in part caused by defects affecting all EVT cells
independently of their location at either the implantation site or cervix.

Recent published

findings (Fritz et al., 2015a) reveal a strong correlation early in gestation between cervical EVT
expression patterns of several proteins suspected of involvement in uteroplacental insufficiency
and adverse pregnancy outcomes such as EPL (Fritz et al., 2015a). The exact origin and biology
of EVT-like cells residing in the cervix, and their relationship to the human placenta and
pregnancy outcomes, are widely unknown. Based the information gathered so far, it can be
hypothesized that, as the placenta grows, EVT cells are naturally shed into the cervical canal, and
their overall phenotype is comparable to the EVT cells residing in the placenta. Any differences
found in their RNA expression profiles could reflect the influences of the respective local
environments. Previously, investigators have tried to harness the cervical cells, but have failed
to get a pure population. In this study, for the first time using TRIC it has been possible to study
the transcriptomic signature of EVT like fetal cells that were obtained in a noninvasive fashion
as early as 5 week of gestation and utilize them as an experimental paradigm to investigate
placental pathophysiology.
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Figure 27. Pathway Analysis for EPL. Potential regulatory networks identified by Genomatix pathway
analysis for genes differentially expressed between fetal EPL and control pregnancies. A. Apoptosis. B.
Inflammation. C. Placental disease. Upregulated genes represented in red, downregulated in blue, and no
regulation in orange, according to the key at bottom of figure.
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TRIC provides ample RNA from isolated EVT cells for extensive transcriptomic
analysis. Statistical analysis of TRIC/RNAseq data revealed 428 genes differed significantly
(Figure 22) between cervical EVT and maternal cells of which trophoblast specific genes were
validated using RT-PCR. mRNA expression of cervical EVT cells showed not only higher
expression trophoblast markers such as HLA-G and KRT7 but also a higher expression of
invasion/migration markers like CDH5 and MMP9. Additionally, lower expression of epithelial
markers like CDH1 and ITGA6 was also seen in these EVT like fetal cells.
Expression of trophoblast specific markers, trophoblast invasion/migration markers and
epithelial markers suggests an epithelial -mesenchymal transition (EMT). During implantation
and subsequent placentation cells of the trophectoderm that are known to be precursors of
cytotrophoblast undergo EMT that induces trophoblast invasion and anchoring of the villi into
maternal decidua to promote nutrient and gas exchange (Aplin et al., 1998; Bischof et al., 2006;
Vicovac and Aplin, 1996). EMT results in the loss of junction and polarity of epithelial cells
results in a reorganization of their cytoskeleton, reprogramming of gene expression and initiation
of increased motility and invasive phenotype (Thiery et al., 2009; Thiery and Sleeman, 2006).
Interestingly, bioinformatics analysis on the differentially regulated genes between the maternal
and EVT like fetal cells generated pathways involved in invasion, migration and proliferation as
the top scored (Figure 24). Based on the mRNA expression of cells isolated by TRIC it can
therefore be hypothesized that the isolated cells are indeed EVT like and could have undergone
EMT.
Overall, this data indicated the expected phenotypic similarities of the two trophoblast
populations, and suggested that cervical EVT were mostly fully differentiated EVT. Based on
these findings, we conclude that cDNA libraries can be constructed from RNA isolated cervical
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EVT cells and reproducibly sequenced by NGS. Furthermore, libraries produced from different
cell types show expected differences. Significant differences were measured in gene expression
between first trimester samples with early pregnancy loss and normal term deliveries (Figure25).
A comparison of the EVT like fetal cells from normal term deliveries and those from early
pregnancy loss generated a total of 348 differentially expressed genes. Of these some of the
genes upregulated in the EPL group such as FOS (Sitras et al., 2009), IL1B (Hefler et al., 2001),
IL8 (Shimoya et al., 1999) and NFƘB(Vaughan and Walsh, 2012) have been reported to be
associated with placental insufficiencies such as PE, IUGR and recurrent pregnancy loss based
on studies done using placental tissue or from maternal serum. Bioinformatics pathway analysis
of the differentially expressed genes in pregnancies with EPL represented several interesting
pathways, including inflammation, apoptosis and placental disease (Figure 27). These are not
unexpected findings, and they support the validity of our data. TRIC provides the platform to
now study these genes on a global aspect. Transcriptome signatures associated with poor
placentation will identify novel targets for preclinical testing with very high sensitivity and
specificity. This avenue of translational investigation will significantly accelerate our ability to
diagnose and monitor perinatal disease, and is likely to facilitate experimental and clinical
breakthroughs beneficial to patients who succumb to obstetrical disorders that arise from
uteroplacental insufficiency.
Due to the fact that EVT invasion and conversion of maternal spiral arteries occurs in the
first and early second trimesters, the unique transcriptomes of patients with disease arising from
poor placentation will help to identify new biomarkers for assessment of disease risk. Though,
the heterogeneous nature of these pathologies and variations in patient genetics and
environmental factors gives rise to differences in expression of some genes among individual
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specimens within each cohort. Yet this platform has, for the first time, made it possible to tract
the changes in EVT physiology and identifies many new potential biomarkers. This study will
help unravel molecular mechanisms governing uteroplacental insufficiency and the lay the
foundation for subsequent studies to evaluate larger cohorts. TRIC is a novel platform for
noninvasive, real time placental assessment, and pre-clinical prediction of specific abnormal
pregnancy outcomes. It provides the means to identify patients at high risk for disease as a
research tool for evaluating first trimester interventions and new patient management strategies.
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CHAPTER 6 - CONCLUSION
Two approaches were undertaken to investigate the etiology of placental insufficiency.
The first involved a focused study of HBEGF, which was known to regulate trophoblast survival
and invasion, and becomes dysregulated in PE (Brosens et al., 1972; DiFederico et al., 1999).
Secondly, an unbiased global approach based on NGS and systems biology to explore the EVT
transcriptome by leveraging a novel, innovative approach to capture EVT like cells noninvasively from ongoing pregnancies.
Previous studies indicated that HBEGF is post-transcriptionally regulated by O2 through
a dual mechanism in which proHBEGF is cleaved by metalloproteinases at low O2, and the
released sHBEGF induces downstream signaling through MAPKs to mobilize its dormant
mRNA (Armant et al., 2006; Jessmon et al., 2010). Using an established trophoblast cell line
and a villous explant model, we have established a role for HSPA6 (HSP70B’), a HIF-regulated
gene, in the upregulation of MMP2 required for HBEGF shedding and subsequent survival
signaling at low O2 (Chapter 2). These key components of the trophoblast survival pathway
could be required during early placentation and their disruption could contribute to placental
insufficiency.
To further investigate the upregulation of HBEGF by low O2, we examined the pathway
downstream of its shedding, which autoregulates its accumulation. The goal was to determine
how dormant HBEGF mRNA becomes translated, hypothesizing that miRNA is involved.
Global analysis of miRNA by RNAseq demonstrated that the mechanism did not involve a
change in miRNA expression.

Demonstration for a role of the miRNA through DGCR8

knockdown with siRNA suggested that other components of the RISC could contribute to the
regulation of HBEGF mRNA translation (Chapter 3). The elucidation of this complex regulatory
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mechanism could provide important insights into trophoblast survival during early placentation,
and its disruption in pregnancies with developmental pathologies. However, HBEGF and other
components of the EGF signaling system are disrupted in placentas of women with PE (Armant
et al., 2015; Leach et al., 2002a). Previous studies have shown that the survival and invasive
function of EVT cells is under the regulation of numerous pathways involving growth factors,
cell surface proteins and extracellular matrix components (Cross et al., 1994; Fritz et al., 2014;
Lala and Hamilton, 1996). Therefore, there is need to study trophoblast development using a
global platform.
TRIC is a novel approach to non-invasively acquire EVT cells hypothesized to be central
for proper placentation during the first half of pregnancy. Using rigorous genetic analysis of
cells isolated by TRIC, we have shown that they are indeed fetal in origin (Chapter 4).
Additionally, isolation of fetal cells by TRIC followed by NGS provides an advantageous
platform for perinatal diagnostics as that is the first to offer noninvasive fetal genetic and
perinatal disease testing as early as 5 weeks of gestation, which compares favorably to the
current available options.
We applied the TRIC platform to investigate the transcriptome of fetal cells from
ongoing pregnancies with known outcomes as a strategy to identify molecules contributing to
placental insufficiencies (Chapter 5).

Evidence was provided that cells obtained by TRIC

expressed many known trophoblast markers, indicating an EVT phenotype. Therefore, TRIC
can provide a novel window into the molecular mechanisms controlling EVT cells during
development and pathology. Based on their expression of genes associated with the EVT
phenotype, it is interesting to note that displacement to the cervix has not greatly altered these
cells due to a new environment. Further analysis by direct comparison to authentic EVT cells is
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necessary to establish the extent of impact from this dislocation. Our pilot study provides an
initial view of transcripts that are differentially expressed between EVT cells of normal term
pregnancies and those that end in an EPL. Here, we postulate that EPL is the result of severe
placental insufficiency. In using TRIC, we are the first to examine EVT cells in the first
trimester from pregnancies with known outcomes.

We can report, based on the altered

expression of 348 genes, that the EVT cells are indeed disrupted in placental insufficiencies, as
long hypothesized (Burton and Jauniaux, 2004).
Fritz et al, found a half-dozen proteins that altered in EVT cells from the cervix of
patients that had an EPL, compared to those with a normal term pregnancy (Fritz et al., 2015a),
confirming expectations based on published changes in serum levels of those proteins at much
later times during gestation. Recent studies demonstrated the same protein changes in cervical
EVT cells from patients that later developed FGR or PE (Bolnick et al., in press), suggesting a
relationship between those proteins and EVT failure to remodel the spiral arteries prior to
placental insufficiency. It would be interesting to determine global molecular changes in EVT
cells associated with disease, using transcriptomic, proteomic and other systems biology
approaches. Here, we have found through bioinformatics differences between EVT and maternal
cells indicative of EMT. Additionally, the differentially expressed genes in pregnancies with
EPL represented several interesting pathways, including inflammation, apoptosis, placental
disease and gestation trophoblastic disease. These are not unexpected findings, and they support
the validity of our data. Future pre-clinical studies with greater sample numbers should be
conducted to firmly establish molecular profiles of control and disease pregnancies to provide
insight into changes in signaling pathways associated with placental insufficiencies.
Comparisons among cohorts of EVT cells obtained by TRIC that are associated with
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normal or adverse pregnancy outcomes could provide an in-depth validation that these cells
accurately reflect pathologies arising from EVT deficiencies, as supported by our data. These
studies will provide a clearer view of the utility of EVT cells as a platform for perinatal testing to
predict maternal risk of placenta-based disease. The current choice of biomarkers for adverse
outcomes is limited to a few found in serum, usually late in gestation. Screening the fetal
genome, proteome and transcriptome by TRIC during the first trimester will expand the pool of
potential biomarkers by several orders of magnitude.
Although neither HBEGF nor MMP2 gene expression was altered by EPL, we did find a
decrease in expression of HSP90B. HSP90 works with HSP70 (Hernandez et al., 2002; Wegele
et al., 2004), a critical gene in HBEGF upregulation (Chapter 2). Based on findings in Chapters
2 and 3, we know that HBEGF is post-transcriptionally regulated. In the future, proteomics could
be used to investigate components of the RISC affected by placental insufficiency that could be
involved in HBEGF regulation.

While the studies in this dissertation have raised many

questions, the findings provide a way forward towards understanding mechanisms that regulate
trophoblast survival and differentiation using the TRIC platform in conjunction with a systems
biology approach.
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HBEGF, is present in the uterus at the time of embryo implantation and protects first
trimester TB cells from apoptosis and promotes their invasion. The hypertensive disease, PE, in
which TB invasion of the uterine arteries is reduced and TB apoptosis is elevated, is
characterized by a reduction in HBEGF expression. In this study using a first trimester cell line
and villous explant culture key components involved in HBEGF survival signaling pathway were
identified. Specific MMP inhibitors established the requirement for MMP2 in HBEGF shedding
and upregulation. NGS identified a HIF regulated gene, HSPA6 (HSP70B’) and using specific
inhibitors it was established that HSP70 regulates MMP2 mediated shedding of HBEGF at low
O2 and is functional upstream of MAPKs signaling cascade. To further investigate HBEGF
upregulation at low O2 using NGS and siRNA knockdown of DGCR8 it was demonstrated that
other components of RISC may be involved in regulation of HBEGF mRNA translation. These
findings suggest that trophoblast survival during early pregnancy requires this signaling pathway
and disruption of any component could lead to placental insufficiency. However, a global
platform is needed to study the pathophysiology of trophoblast cells and their role in placental
insufficiency.

153
TRIC is an innovative platform to noninvasively acquire fetal cells. DNA was extracted
from fetal cells isolated from 20 specimens with gestational age as early at 5 weeks to 19 weeks.
This was followed by targeted sequencing using the Forenseq (Illumina) platform to identify
informative SNPs. Using the Forenseq software 89% ± 12% of the 94 SNPs were called
correctly in the fetal samples. Using the STR analysis out of the 20 fetal samples, 9 males were
confirmed. Therefore, TRIC not only provides fetal cells but also opens new venues of perinatal
testing.
TRIC provides ample RNA from isolated fetal cells for extensive transcriptomic analysis.
Using qPCR it was demonstrated that the fetal cells have higher expression for EVT specific
markers such as HLA-G and KRT7 and markers for invasion/migration such as CDH5 and
MMP9, whereas the maternal cells have a higher expression for epithelial markers such as CDH1
and ITGA6. This suggests that not only are the fetal cells EVT like but may also undergo an
epithelial mesenchymal transition. Comparison of fetal and maternal cells from normal group
using NGS identified 409 genes, of which top 5 upregulated and downregulated genes were
validated by qPCR. Pathway analysis of the differentially regulated identified pathways related
to invasion/migration, proliferation and differentiation, further suggesting the EVT like
expression of the fetal cells. NGS revealed 348 differential expressed genes on comparison of
the EVT like fetal cells from the EPL group to those from the normal group that were further
validated by qPCR.

Bioinformatic analysis identified pathways related to apoptosis,

inflammation and placental disease.
The exact origin and biology of cervical EVT cells, and their relationship to the human
placenta and pregnancy outcomes, are widely unknown. Based on our study so far it can be
hypothesized that as the placenta grows, EVT cells are naturally shed into the cervical canal, and
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their overall phenotype is comparable to the EVT cells residing in the placenta. These studies
will provide a clearer view of the utility of EVT cells obtained by TRIC from ongoing
pregnancies for investigating early placentation and mechanisms of pathology, and their potential
as a platform for prenatal tests to predict maternal risk of placenta-based disease.
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